WO2021086017A1 - Composition for muscular function enhancement comprising ginsenoside rf, ginsenoside composition comprising ginsenoside rf, or mixture of any one or more thereof as active ingredient - Google Patents

Composition for muscular function enhancement comprising ginsenoside rf, ginsenoside composition comprising ginsenoside rf, or mixture of any one or more thereof as active ingredient Download PDF

Info

Publication number
WO2021086017A1
WO2021086017A1 PCT/KR2020/014832 KR2020014832W WO2021086017A1 WO 2021086017 A1 WO2021086017 A1 WO 2021086017A1 KR 2020014832 W KR2020014832 W KR 2020014832W WO 2021086017 A1 WO2021086017 A1 WO 2021086017A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginsenoside
composition
weight
mixture
muscle
Prior art date
Application number
PCT/KR2020/014832
Other languages
French (fr)
Korean (ko)
Inventor
이영경
김경탁
신은주
이영철
임원철
임태규
조장원
최재웅
홍희도
송노을
Original Assignee
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국식품연구원 filed Critical 한국식품연구원
Priority claimed from KR1020200140963A external-priority patent/KR102483300B1/en
Publication of WO2021086017A1 publication Critical patent/WO2021086017A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/51—Concentration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/2124—Ginseng

Definitions

  • the present invention is a ginsenoside Rf, ginsenoside composition comprising a ginsenoside Rf, or a food composition for improving muscle function, such as increasing exercise capacity, increasing muscle strength or increasing muscle mass, comprising a mixture of one or more of them as an active ingredient, It relates to a cosmetic composition for improving muscle function, a food composition for improving or preventing sarcopenia, or a pharmaceutical composition for treating or preventing sarcopenia.
  • Skeletal muscle is an organ that occupies the largest part of the human body and accounts for 40-50% of the total body weight, and plays an important role in various metabolic functions in the body, including energy homeostasis and heat generation.
  • Human muscles decrease by more than 1% every year from the age of 40, and by the age of 80, the level of maximum muscle mass decreases by 50%, and the loss of muscles in old age is recognized as the most important factor that degrades overall physical function.
  • the body shape changes such as the content of muscle and fat, and skeletal distortion, and the prevalence of obesity due to muscle loss in old age is showing a continuous increasing trend at a level of 30% or more worldwide.
  • sarcopenia is also closely related to senile chronic diseases such as osteoporosis, insulin resistance and arthritis, and it is possible to suppress a decrease in physical activity due to aging through the prevention or improvement of sarcopenia.
  • the global advanced ataxia and muscle weakness treatment market reached about $14 billion in 2011, and is expected to grow at a compound annual growth rate of 9.4% since then, reaching about $23.5 billion in 2017.
  • a food composition for improving muscle function such as increasing exercise capacity, muscle strength, or muscle mass increase, using natural substances that are safe to consume for sarcopenia patients or the elderly and can be taken for a long time
  • cosmetic composition for improving muscle function, improvement or prevention of sarcopenia There is a demand for a food composition or a pharmaceutical composition for the treatment or prevention of sarcopenia.
  • ginsenoside Rg1 or Rb1 among the active ingredients of ginseng is related to muscle differentiation, but ginsenoside Rf, which is not contained in Hwagisam and is characteristic of Korean ginseng, It has not been revealed whether it is relevant.
  • Ginsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube growth, 2017, Journal of Ginseng Research
  • Ginsenoside Rb1 and Rb2 upregulate Akt/mTOR signaling emediated muscular hypertrophy and myoblast differentiation, 2019, Journal of Ginseng Research
  • An object of the present invention is to provide a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
  • Another object of the present invention is to provide a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
  • Another object of the present invention is to provide a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving or preventing sarcopenia comprising a mixture of one or more of them as an active ingredient It is to do.
  • Another object of the present invention is to provide a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a pharmaceutical composition for the treatment or prevention of sarcopenia comprising a mixture of one or more of them as an active ingredient It is to do.
  • the present invention for achieving the above object provides a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving muscle function comprising a mixture of one or more of them as an active ingredient.
  • the present invention provides a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
  • the present invention provides a ginsenoside Rf, a ginsenoside composition comprising a ginsenoside Rf, or a food composition for improving or preventing sarcopenia comprising a mixture of one or more of them as an active ingredient.
  • the present invention provides a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a pharmaceutical composition for the treatment or prevention of sarcopenia comprising a mixture of at least one of them as an active ingredient.
  • a ginsenoside composition comprising ginsenoside Rf, or a mixture of any one or more of them promotes the expression of Myosin Heavy Chain, a muscle differentiation marker, regulates energy homeostasis in the body, and develops and grows skeletal muscle It promotes phosphorylation of AMPK, which plays an important role in regulation, and can increase exercise capacity, increase muscle strength, increase muscle mass, and alleviate muscle atrophy by increasing swimming duration in the forced swimming test in animal experiments.
  • FIG. 1 is a photograph confirming the expression of MHC (Myosin Heavy Chain) when ginsenosides Rf, Rb2 and Rg1 were treated with 10, 20 and 40 ⁇ M, respectively, through Western blot.
  • MHC Myosin Heavy Chain
  • FIG. 2 is a graph comparing the size of the western blot band representing the expression of MHC (Myosin Heavy Chain) of FIG. 1 with respect to actin.
  • FIG. 3 is a photograph confirming phosphorylation of 5′-adenosine monophosphate-activated protein kinase (AMPK) when ginsenosides Rf, Rb2 and Rg1 were treated with 10, 20 and 40 ⁇ M, respectively, through Western blot.
  • AMPK 5′-adenosine monophosphate-activated protein kinase
  • Figure 4 is a relative expression level of the western blot band size of phosphorylated p-AMPK (phosphorylated 5'-adenosine monophosphate-activated protein kinase) of Figure 3 for non-phosphorylated AMPK (phosphorylated 5'-adenosine monophosphate-activated protein kinase) It is a graph comparing.
  • FIG. 5 shows MHC, PGC-1 ⁇ , phosphorylated p-AMPK, phosphorylated p38 when 10 ⁇ M of ginsenoside Rf and 0.2, 1, and 5 ⁇ M of ginsenosides Rh1 and Rg2, respectively, were confirmed through Western blot. It's a picture.
  • FIG. 6 is a graph comparing the relative expression levels of MHC, PGC-1 ⁇ , phosphorylated p-AMPK, and phosphorylated p38 to actin of FIG. 5.
  • FIG. 8 is a graph comparing the relative expression levels of MHC, PGC-1 ⁇ , phosphorylated p-AMPK, and phosphorylated p38 to actin of FIG. 7.
  • the present invention relates to a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
  • the present invention relates to a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
  • the present invention also relates to a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving or preventing sarcopenia comprising a mixture of at least one of them as an active ingredient.
  • the present invention relates to a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a pharmaceutical composition for the treatment or prevention of sarcopenia comprising a mixture of one or more of them as an active ingredient.
  • the composition may further include a ginsenoside composition including ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of them.
  • the composition comprises 1 to 100 parts by weight, 2 parts by weight or more, 5 parts by weight or more, 10 parts by weight or more, 20 parts by weight or more, 30 parts by weight or more, 40 parts by weight, based on 100 parts by weight of the ginsenoside Rf component. It may be at least 90 parts by weight, 80 parts by weight or less, 70 parts by weight or less, and 60 parts by weight or less.
  • the ginsenoside composition comprising the ginsenoside Rf may be a ginsenoside Rf concentrate obtained by treating a plant of the genus Panax or an extract thereof by any one or more processes selected from heating, enzyme treatment, and fermentation.
  • the ginsenoside composition comprising the ginsenoside Rh1 may be a ginsenoside Rf concentrate obtained by treating a plant of the genus Panax or an extract thereof by any one or more processes selected from heating, enzyme treatment, and fermentation.
  • the plant extract of the genus Panax may be an extract using water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
  • the water is suitable for food production, there is no need to specifically limit it, but for example, ground water, purified water, distilled water, deionized water, and the like may be used.
  • the alcohol having 1 to 4 carbon atoms is not particularly limited, but for example, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol or normal-butanol may be used, preferably ethanol.
  • the mixed solvent is not particularly limited, but for example, in the case of a mixed solvent of water and ethanol, 5 to 95% by weight aqueous ethanol solution, 10 to 90% by weight aqueous ethanol solution, 20 to 80% by weight aqueous ethanol solution, 30 to 70% by weight An aqueous ethanol solution can be used.
  • the preparation of the water extract is not particularly limited, but can be prepared by extracting the plant of the genus Panax with water at 10 to 100° C. for 2 to 60 hours.
  • the preparation of the alcohol extract or the extract of a mixed solvent of water and alcohol is not particularly limited, but, for example, the plant of the genus Panax is prepared by extracting the genus Panax with an aqueous ethanol solution of 30 to 70% by weight at 20 to 60°C for 2 to 48 hours. do.
  • Plants of the genus Panax are Korean ginseng (Panax ginseng), Hwagi ginseng (Panax quinquefolia), Panax notoginseng, bamboo japonica, Panax trifolia, Himalayan ginseng (Panax pseudoginseng), Vietnamese ginseng (Panax vietnamensis). ) And may be any one or more selected from cultured roots thereof.
  • the plant of the genus Panax may be any one or more selected from roots, seeds, fruits, and leaves of the plant.
  • the ginsenoside composition comprising the ginsenoside Rf or the ginsenoside composition comprising ginsenoside Rh1 is an extract of the genus Panax plant, a fraction fractionated from them, a concentrate obtained by additionally concentrating these extracts or fractions, Purified or separated purified product is also included, and the extract, fraction, concentrate, or purified product is dried or pulverized.
  • various additionally performed such as passing through an ultrafiltration membrane having a molecular weight cut-off value, or separation by various chromatography (made for separation according to size, charge, hydrophobicity, or affinity) Purification methods can be added.
  • composition that is, 1) a ginsenoside composition comprising ginsenoside Rf, or 2) a mixture of a ginsenoside composition comprising ginsenoside Rf and ginsenoside Rf, or 3) ginsenoside Rf, ginseno A ginsenoside composition comprising a side Rf, or a mixture of any one or more of them; and a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of these; a mixture of ginsenosides Ginsenoside Rf 30% by weight or more, 35% by weight or more, 40% by weight or more, 45% by weight or more, 50% by weight or more, 60% by weight of the total ginsenoside weight consisting of the sum of Rf, Rh1, Rg1 and Rb2 It may contain more than, or 70% by weight or more, and may contain 80% by weight or less, 90% by weight or less, 95% by weight or less, 99% by weight
  • composition that is, 1) a ginsenoside composition comprising ginsenoside Rf, or 2) a mixture of a ginsenoside composition comprising ginsenoside Rf and ginsenoside Rf, or 3) ginsenoside Rf, ginseno A ginsenoside composition comprising a side Rf, or a mixture of any one or more of them; and a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of these; Ginsenoside Rf of 20% by weight or more, 22% by weight or more, 25% by weight or more, 30% by weight or more, 35% by weight or more, 40% by weight or more, 45% by weight or more, 50% by weight of the total weight of all ginsenosides It may contain more than, 60% by weight or more, or 70% by weight or more, and also include 80% by weight or less, 90% by weight or less, 95% by weight or less, 99% by weight or less, or 100%
  • composition that is, 1) a ginsenoside composition comprising ginsenoside Rf, or 2) a mixture of a ginsenoside composition comprising ginsenoside Rf and ginsenoside Rf, or 3) ginsenoside Rf, ginseno A ginsenoside composition comprising a side Rf, or a mixture of any one or more of them; and a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of these; a mixture of ginsenosides Ginsenoside Rf in the total weight of 10% by weight or more, 12% by weight or more, 15% by weight or more, 20% by weight or more, 25% by weight or more, 30% by weight or more, 35% by weight or more, 40% by weight or more, 45% by weight % Or more, 50% by weight or more, 60% by weight or more, or 70% by weight or more, and also 80% by weight or less, 90% by weight or less, 95% by weight
  • the term'contained as an active ingredient' means 1) ginsenoside Rf, 2) ginsenoside composition comprising ginsenoside Rf, or 3) any one or more mixtures of these, or 4) ginsenoside Rf, ginseno A ginsenoside composition comprising a side Rf, or a mixture of any one or more of them; and a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of these; Achieving the efficacy of a mixture of It means to contain enough amount to do.
  • muscle function improvement refers to tendons, muscles, and tendons generically, and'muscle function' refers to the ability to exert power by contraction of muscles.
  • Muscle strength capable of exerting contractility
  • Muscle endurance the ability to describe how long or how many times a muscle can contract and relax for a given weight
  • instantaneous power which is an ability to exert a strong power within a short time.
  • the improvement of muscle function may be any one selected from an increase in exercise capacity, an increase in muscle strength, and an increase in muscle mass.
  • the sarcopenia refers to a disease in which muscle volume and muscle strength gradually decline due to muscle function decline, muscle wasting or muscle degeneration, and muscle atrophy, myasthenia, muscle dystrophy, muscle stiffness, muscle tone reduction, muscle weakness, muscle regression, muscle atrophy. It may be any one selected from lateral sclerosis and myasthenia gravis.
  • the present invention relates to a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving muscle function or improving or preventing sarcopenia, comprising a mixture of one or more of them as an active ingredient.
  • the food composition may further include a ginsenoside composition including ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of them.
  • the'food composition' is a standard and standard of food commonly used in food production ('food Food ingredients and food additives that can be used as foods described in the code') include food additives described in the code.
  • the carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sugar, lactose, and the like; Oligosaccharides or polysaccharides such as dextrin, starch syrup, cyclodextrin, and the like; Sugar alcohols such as xylitol, sorbitol, erythritol, and the like can be used.
  • the flavoring agent may be a natural flavoring agent [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and a synthetic flavoring agent (saccharin, aspartame, etc.).
  • Ginsenoside comprising ginsenoside Rf, ginsenoside Rf when preparing a food composition using the ginsenoside Rf, ginsenoside Rf, or a mixture of any one or more of them as an active ingredient
  • the composition, or a mixture of any one or more thereof does not need to be particularly limited as long as it is an amount exhibiting an effect of improving muscle function or sarcopenia, but, for example, 0.1 to 99% by weight, 0.5 to 95% by weight, 1 to 90% by weight, It may be included in 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, and 5 to 50% by weight.
  • the ginsenoside composition comprising ginsenoside Rf and ginsenoside Rf, which are active ingredients in the food composition, or a mixture of any one or more of them varies depending on the condition of the ingestor, weight, the presence or absence of disease, and the duration, but usually It can be appropriately selected by the technician of For example, it may be 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, even more preferably 20 to 800 mg, most preferably 50 to 500 mg, based on the daily dosage.
  • the number of administrations does not need to be particularly limited, but can be adjusted by a person skilled in the art within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, it may be less than the above range.
  • the food composition is not particularly limited, but may be, for example, a powder, a granule, a tablet, a capsule, a pill, an extract, a jelly formulation, a tea bag formulation, or a beverage formulation.
  • a ginsenoside composition including the ginsenoside Rf and ginsenoside Rf, or a mixture of any one or more of these may be added in order to impart the function of improving muscle function or sarcopenia to general foods due to ultraviolet rays.
  • Foods that can be allowed are not particularly limited, but for example, confectionery, bread or rice cakes, processed cocoa products or chocolates, meat or eggs exemplified in the food standards and standards ('Food Code') according to Article 7 of the Food Sanitation Act.
  • Processed products processed fish products, tofu or jelly, noodles, tea, coffee, beverages, special purpose foods, pastes, seasoned foods, dressings, kimchi, salted fish, pickles, stewed foods, alcoholic beverages, raisins, and other foods.
  • dairy products processed meat products and packaged meats, and egg products as exemplified in the processing standards and ingredient specifications of livestock products pursuant to Article 4 of the Livestock Hygiene Management Act ('Livestock Products Code').
  • the ginsenoside composition comprising the ginsenoside Rf, ginsenoside Rf, or a food composition comprising any one or more of these as an active ingredient may be used as a "health functional food that helps improve muscle function” It can be used as "health functional food that helps to enhance muscle strength", “health functional food that helps to increase exercise capacity”, or "health functional food that helps to improve sarcopenia”.
  • The'health functional food' refers to a food (including processing) manufactured (including processing) according to legal standards using raw materials or ingredients having useful functions for the human body (Article 3, No. 1 of the Health Functional Food Act).
  • The'health functional food' may differ in terms or ranges from country to country, but'Dietary Supplement' in the United States,'Food Supplemnet' in Europe, and'Health Functional Food' in Japan or ' It may correspond to'Food for Special Health Use (FoSHU)' and'Health Food' in China.
  • the food composition or health functional food may additionally contain food additives, and the suitability as a food additive is determined according to the standards and standards for the relevant item in accordance with the general rules and general test methods of the'Food Additive Code' unless otherwise specified.
  • the health functional food may be used in combination with a ginsenoside composition including the ginsenoside Rf and ginsenoside Rf, or a health functional food material related to improvement of muscle function or sarcopenia with a mixture of one or more of them. have.
  • the present invention relates to a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
  • the cosmetic composition may further include a ginsenoside composition including ginsenoside Rh1, ginsenoside Rh1, or a mixture of one or more of them.
  • the cosmetic composition for improving muscle function When used as the cosmetic composition for improving muscle function, additionally fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water , Ionic emulsifiers, nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic activators, lipophilic activators or lipid vesicles, etc. It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients used as. In addition, the above ingredients may be introduced in an amount generally used in the field of dermatology.
  • the cosmetic composition is not particularly limited, but may be a formulation such as an ointment, patch, gel, cream or spray.
  • the present invention relates to a ginsenoside composition
  • a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a pharmaceutical composition for treating or preventing sarcopenia comprising a mixture of at least one of them as an active ingredient.
  • the pharmaceutical composition may further include a ginsenoside composition including ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of them.
  • the present invention provides a method for treating sarcopenia by administering the composition to humans or animals other than humans.
  • the present invention provides a novel use of a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a mixture of any one or more of them for the manufacture of a medicine for the treatment of sarcopenia.
  • The'pharmaceutical composition' or'medicine' is a ginsenoside composition including ginsenoside Rf and ginsenoside Rf as an active ingredient, or a mixture of any one or more of them, as well as suitable for conventional use in the manufacture of pharmaceutical compositions, etc. It may further include a carrier, excipient and diluent.
  • The'carrier' is a compound that facilitates the addition of the compound into cells or tissues.
  • The'diluent' is a compound that is diluted in water to dissolve the compound as well as stabilize the biologically active form of the target compound.
  • the carrier, excipient and diluent do not need to be particularly limited, but for example, lactose, glucose, sugar, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • the amount of use of the pharmaceutical composition or drug may vary depending on the age, sex, and weight of the patient or the animal to be treated, and above all, the condition of the subject to be treated, the specific category or type of the disease to be treated, the route of administration, and the therapeutic agent used. It will be attribute dependent.
  • the pharmaceutical composition or medicament is appropriately selected according to the degree of absorption of the active ingredient in the body, the excretion rate, the age and weight, sex and condition of the patient or the animal to be treated, the severity of the disease to be treated, etc.
  • the unit dosage form formulation thus formulated can be administered several times at regular time intervals as needed.
  • the pharmaceutical composition or medicament may be individually administered as a prophylactic or therapeutic agent, or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent.
  • compositions or drugs may be formulated and used in oral dosage forms such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc., according to conventional methods.
  • oral dosage forms such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc.
  • diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, and the like, and these solid preparations include at least one excipient for the compound, such as starch, calcium carbonate, sugar or lactose, gelatin. It can be prepared by mixing and the like. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
  • Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. .
  • the method for treating sarcopenia is a ginsenoside composition comprising 1) ginsenoside Rf, 2) ginsenoside Rf, or 3) a mixture of any one or more of these in humans or non-human animals, particularly mammals. , Or 4) ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or any one or more mixtures thereof; and ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or among these
  • a mixture of any one or more mixtures for example, a ginsenoside composition comprising the ginsenoside Rf, ginsenoside Rf, or a mixture of any one or more thereof to an individual to be treated with sarcopenia It is administered orally.
  • Whether or not the subject to be treated with sarcopenia may be the case where the amount of skin moisture loss is increased, the skin moisture content is decreased, the roughness of the skin is increased, and the elasticity of the skin is decreased.
  • the dosage, administration method, and number of administrations for the treatment may refer to the dosage, administration method, and number of administrations of the pharmaceutical composition or drug.
  • MHC myosin heavy chain
  • C2C12 muscle cells were purchased and used from the American Type Culture Collection (ATCC). C2C12 muscle cells were cultured in a DMEM medium containing 10% FBS and 1% antibiotic in an incubator at 37°C and 5% CO2. When replacing with 2% horse serum DMEM medium, muscle differentiation is induced, and ginsenosides Rf, Rg1 and Rb2 are treated 2 days after treatment with differentiation inducing conditions (DM, 2% horse serum DMEM medium) in muscle cells (C2C12). Did
  • the cell pellet prepared by the above method was prepared using a cell lysis buffer (cell signaling) to which a protease inhibitor and a phosphatase inhibitor were added.
  • cell signaling cell signaling
  • the same amount of the protein is mixed with the SDS sample buffer and heated at 95° C. for 10 minutes to denature the protein to be used in the experiment.
  • Samples were electrophoresed on gradient SDS-polyacrylamide gel. After transferring the protein of the gel to a nitrocellulose (NC) membrane, blocking is performed for 1 hour at room temperature with a 5% skim milk solution. Thereafter, the primary antibody was incubated overnight at 4° C., and then the appropriate secondary antibody with HRP was added, and the expression of each protein was confirmed by chemiluminescent method using an ECL solution, as shown in FIG. 1.
  • ginsenoside Rg1 The muscle differentiation efficacy of ginsenoside Rg1 is described in "Ginsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube growth, 2017, Journal of Ginseng Research". As described in myoblast differentiation and myotube growth, 2017, Journal of Ginseng Research", these ginsenosides were used as positive controls.
  • ginsenoside Rf compared to ginsenosides Rg1 and Rh2, which are known for their muscle differentiation efficacy (see FIGS. 1 and 2).
  • ginsenoside Rf increased muscle differentiation efficacy by 4.1 times compared to ginsenoside Rg1
  • ginsenoside Rf increased muscle differentiation efficacy by 5.3 times compared to ginsenoside Rb2.
  • AMPK (5'-adenosine monophosphate-activated protein kinase) is a major enzyme that regulates energy homeostasis in the body and is known to play an important role in skeletal muscle development and growth regulation. Changes in AMPK phosphorylation, a signal protein related to energy metabolism by treatment with ginsenosides Rf, Rb2 and Rg1, were confirmed using the Western blot method of Experimental Example 1, and the results are shown in FIGS. 3 and 4.
  • Ginsenosides Rf, Rb2 and Rg1 treatment all increased phosphorylation of AMPK, a well-known marker related to energy metabolism.
  • ginsenoside Rf significantly increased phosphorylation of AMPK compared to ginsenosides Rb2 and Rg1. Therefore, it can be seen that ginsenoside Rf had an effect on inducing muscle differentiation through AMPK phosphorylation.
  • Ginsenoside Rf is a ginsenoside that is specifically present in Korean ginseng (Panax ginseng) and red ginseng produced therefrom. Ginsenoside Rf works with other ginsenosides to increase muscle differentiation and energy metabolism. It was confirmed whether it showed an effect.
  • Ginsenosides Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 and Rg5 are 7 types of ginsenosides, which are known to increase their content in red ginseng extract compared to white ginseng. Sides were targeted.
  • C2C12 muscle cells prepared in the same manner as in Experimental Example 1 were treated with differentiation inducing conditions (DM, 2% horse serum DMEM medium) 2 days after treatment with ginsenoside Rf 5, 10 and 20 ⁇ M, respectively, and ginsenoside Rh1 with Rf 10 ⁇ M , Rg2, Rk3, Rh4, Rk1, (S)-Rg3 and Rg5 A total of 7 ginsenosides were treated in combination with 0.2, 1 and 5 ⁇ M, respectively.
  • differentiation inducing conditions DM, 2% horse serum DMEM medium
  • Ginsenosides Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 and Rg5 administered in combination with ginsenoside Rf compared to the case of Rf alone treatment only in combination with Rh1 among a total of 7 ginsenosides.
  • the expression of the muscle differentiation biomarker MHC myosin heavy chain was increased, and in particular, when treated with 10 to 50 parts by weight of Rh1 with respect to 100 parts by weight of Rf, it exhibited a synergistic effect (see FIGS. 5 and 6).
  • Hot water extraction was performed 3 times for 2 hours each using a reflux cooling extractor at 80°C with 50 times the amount of distilled water to 1 g of Hwagisam.
  • the supernatant was filtered using Whatman No2 filter paper, concentrated under reduced pressure, diluted again in distilled water, and freeze-dried to prepare a hot water extract of Hwagisam.
  • the Hwagisam hot water extract did not contain ginsenoside Rf, ginsenoside Rg1, 0.32 mg/g, and ginsenoside Rb2, 0.33 mg/g.
  • Ginsenoside composition containing ginsenoside Rf by mixing 10 ⁇ M and 20 ⁇ M of ginsenoside Rf in the Hwagisam hot water extract (100 ⁇ g/mL), ginsenoside in the Hwagi ginseng hot water extract (100 ⁇ g/mL) Ginsenoside composition containing ginsenoside Rg1 by mixing 10 ⁇ M and 20 ⁇ M of Rg1, ginsenoside Rb2 in the Hwagisam hot water extract (100 ⁇ M/mL), respectively, by mixing 10 ⁇ M and 20 ⁇ M of ginsenoside Rb2 Each ginsenoside composition comprising a was prepared.
  • muscle differentiation biomarker MHC myosin heavy chain
  • the ginsenoside composition comprising ginsenoside Rg1, which is a mixture of 10 ⁇ M and 20 ⁇ M of ginsenoside Rg1, respectively, 10 ⁇ M and 20 ⁇ M of ginsenoside Rb2, respectively, and the ginsenoside composition containing ginsenoside Rb2
  • the increase in MHC expression could not be confirmed, the expression of MHC was 1.77 in the ginsenoside composition containing ginsenoside Rf by mixing 10 ⁇ M and 20 ⁇ M of ginsenoside Rf in Hwagisam hot water extract (100 ⁇ g/mL), respectively. It was confirmed that the increase was doubled and 1.6-fold.
  • the above ingredients are mixed and filled in an airtight cloth to prepare a powder.
  • tablets are prepared by tableting according to a conventional tablet manufacturing method.
  • the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.
  • Vitamin A acetate 70 ⁇ g
  • Vitamin B12 0.2 ⁇ g
  • composition ratio of the vitamin and mineral mixture is relatively suitable for granules, but it is also possible to arbitrarily modify the mixing ratio. After mixing the above ingredients according to a conventional granule preparation method, granules And can be used to prepare a health functional food composition according to a conventional method.
  • the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator. It is used to prepare the functional beverage composition of the present invention.
  • composition ratio is a mixture of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ginsenoside Rf, a ginsenoside composition comprising ginsenoside Rf, or a mixture of any one or more thereof, of the present invention, promotes the expression of a myosin heavy chain, which is a muscle differentiation marker, regulates energy homeostasis in the body, promotes the phosphorylation of AMPK, which plays an important role in the regulation of skeletal muscle development and growth, and in the forced swimming test in animal experiments, increases swimming duration, thereby increasing exercise ability, muscle strength, and muscle mass and alleviating muscle atrophy, and thus can be used as a food composition for muscular function enhancement, a cosmetic composition for muscular function enhancement, a food composition for alleviation or prevention of sarcopenia, or a pharmaceutical composition for treatment or prevention of sarcopenia.

Description

진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 조성물A ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a composition for improving muscle function comprising a mixture of at least one of them as an active ingredient
본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 운동능력 증가, 근력 증가 또는 근육량 증가와 같은 근기능 개선용 식품 조성물, 근기능 개선용 화장료 조성물, 근감소증의 개선 또는 예방용 식품 조성물 또는 근감소증의 치료 또는 예방용 약학 조성물에 관한 것이다.The present invention is a ginsenoside Rf, ginsenoside composition comprising a ginsenoside Rf, or a food composition for improving muscle function, such as increasing exercise capacity, increasing muscle strength or increasing muscle mass, comprising a mixture of one or more of them as an active ingredient, It relates to a cosmetic composition for improving muscle function, a food composition for improving or preventing sarcopenia, or a pharmaceutical composition for treating or preventing sarcopenia.
골격근은 인체에서 가장 큰 부분을 차지하는 기관으로 총 몸무게의 40-50%를 차지하며 에너지 항상성 및 열생성 등을 비롯한 체내 여러 대사 기능에도 중요한 역할을 한다. 사람의 근육은 40세 이후부터 매년 1% 이상씩 감소하며, 80세가 되면 최대 근육량의 50% 수준이 감소되고, 노년의 근육 감소는 전반적인 신체기능을 떨어뜨리는 가장 중요한 요소로 인식되어지고 있다. 노화가 진행될수록 근육과 지방의 함량, 골격 왜곡 등 체형이 변화되는 것을 인지하게 되는데, 노년기 근감소에 의한 비만 유병률은 전 세계적으로 30%이상 수준에서 지속적인 증가 추세를 보이고 있다. Skeletal muscle is an organ that occupies the largest part of the human body and accounts for 40-50% of the total body weight, and plays an important role in various metabolic functions in the body, including energy homeostasis and heat generation. Human muscles decrease by more than 1% every year from the age of 40, and by the age of 80, the level of maximum muscle mass decreases by 50%, and the loss of muscles in old age is recognized as the most important factor that degrades overall physical function. As aging progresses, it is recognized that the body shape changes, such as the content of muscle and fat, and skeletal distortion, and the prevalence of obesity due to muscle loss in old age is showing a continuous increasing trend at a level of 30% or more worldwide.
인슐린 분비 이상인 경우 세포에 에너지를 제대로 공급하지 못해 근육발달장애를 일으킬 수 있어, 일반인 보다 당뇨병 환자에게 근감소증이 증가한다. 또한 근육의 감소는 관절염, 허리통증, 만성통증을 더 증가시키는 원인이 되며, 복부비만에 의한 요실금 증세도 악화시킬 수 있고, 골절에 의한 부상은 노년의 우울증을 증가시켜 사망에 이를 수 있기 때문에 노년의 근감소증은 다양한 질환과 연계되어 삶의 질을 떨어뜨리는 주요 원인이 된다. In the case of abnormal insulin secretion, it can cause muscle development disorders due to the inability to properly supply energy to the cells, resulting in increased sarcopenia in diabetics than in the general population. In addition, muscle loss causes arthritis, lower back pain, and chronic pain to increase further, and can worsen urinary incontinence symptoms due to abdominal obesity, and injuries caused by fractures can increase depression in old age and lead to death. Sarcopenia is a major cause of poor quality of life associated with various diseases.
근감소증은 골다공증, 인슐린저항성 및 관절염과 같은 노인성 만성질환과도 밀접한 관계가 있는 것으로 알려져, 근감소증의 예방 또는 개선을 통해서 노화로 인한 신체 활동력의 감소를 억제할 수 있다. 세계의 진행성 운동실조증 및 근력약화 치료제 시장은 2011년 약 140억 달러 규모를 기록했으며 그 이후에는 9.4%의 연평균 복합 성장률로 성장해 2017년에는 약 235억 달러에 이를 것으로 전망되고 있다. It is known that sarcopenia is also closely related to senile chronic diseases such as osteoporosis, insulin resistance and arthritis, and it is possible to suppress a decrease in physical activity due to aging through the prevention or improvement of sarcopenia. The global advanced ataxia and muscle weakness treatment market reached about $14 billion in 2011, and is expected to grow at a compound annual growth rate of 9.4% since then, reaching about $23.5 billion in 2017.
근감소증 환자에서, 근육모세포의 줄기 세포인 위성 세포의 모집, 활성 또는 증식의 장애로 인한 근육모세포(myoblast)의 개수가 감소하며, 근육모세포의 증식 및 분화가 감소하고, 이에 따라 근감소증 환자의 근육은 조직학적인 수준에서 근 섬유의 크기 및 수가 감소하여 근기능이 감소하는 증상이 나타난다. In sarcopenia patients, the number of myoblasts due to impaired recruitment, activity, or proliferation of satellite cells, which are myoblast stem cells, decreases, and the proliferation and differentiation of myoblasts decreases, and accordingly, in sarcopenia patients. At the histological level, muscle decreases in the size and number of muscle fibers, resulting in decreased muscle function.
과거 10여년간 미국 및 유럽을 중심으로 근감소증의 역학에 대한 연구가 활발히 이루어지면서 최근에 근감소증의 임상적 중요성에 대한 관심이 폭증하고 있다. 초기 연구에서는 근감소증이 전신 쇠약, 활동 장애 및 근력 감소에 의해 삶의 질 저하를 유발한다는 결과들이 주류를 이루었지만, 최근 발표되는 연구들에서는 삶의 질 이외에도 골다공증성 골절 위험이 현저히 증가할 수 있음이 보고되었다. 또한, 근감소증 환자에서 당뇨병 및 대사증후군, 비만, 만성 신부전, 만성 간부전 등의 만성 질환이 유발되며, 궁극적으로는 사망률도 증가시키기 때문에, 근감소증은 적절하게 치료받아야 하는 질환으로서 관심이 집중되고 있다.As research on the epidemiology of sarcopenia has been actively conducted in the United States and Europe for the past 10 years, interest in the clinical significance of sarcopenia is exploding in recent years. In early studies, results that sarcopenia caused a decrease in quality of life due to general weakness, impaired activity, and decreased muscle strength, but recently published studies may significantly increase the risk of osteoporotic fractures in addition to quality of life. Was reported. In addition, since chronic diseases such as diabetes and metabolic syndrome, obesity, chronic renal failure, and chronic liver failure are induced in sarcopenia patients, and ultimately increase mortality, sarcopenia is a disease that needs to be treated appropriately. .
최근 미국에서는 근감소증 환자에서 신체장애가 발생할 가능성이 약 1.5배 내지 약 3.5배가 증가함으로써 연간 185억 USD의 사회적 비용을 유발한다고 보고된 바 있다. 우리나라에서는 국민건강영양조사에 따르면 근감소증 유병률은 60세 이상 남성의 42.0%와 여성의 42.7%로 매우 흔한 질환이며, 특히 우리나라는 전세계에서도 고령화 속도가 높기 때문에 향후 중요한 사회적 문제가 될 것이 확실하다.Recently, in the United States, it has been reported that the likelihood of developing a physical disability in sarcopenia patients increases by about 1.5 to about 3.5 times, causing a social cost of 18.5 billion USD per year. In Korea, according to the National Health and Nutrition Survey, the prevalence of sarcopenia is 42.0% of men over 60 years old and 42.7% of women, and it is a very common disease.In particular, since Korea has a high rate of aging in the world, it is certain that it will become an important social problem in the future.
현재 근감소증에는 운동, 단백질 및 칼로리보충이 도움이 된다고 알려져 있으나, 근감소증 환자의 대부분을 차지하는 노인들에서는 크게 도움이 되지 않아 근감소증 치료제가 절실히 필요하다. 그러나, 현재 근감소증에 사용되는 치료제들은 근육감소 개선 및 근육량 증진에 직접적인 효과를 나타내는 약물은 아직까지 임상실험 수준의 단계이며, 현재 최종적으로 FDA 승인을 받은 약제는 없는 상황이다. 때문에 근감소증 치료를 위해서 일부 selective androgen receptor modulator, activin receptor antagonist, fast skeletal muscle troponin inhibitor 등을 근감소증 치료제로 개발하려는 노력들은 있으나, 현재 초기 임상을 시도하는 수준이다.Currently, exercise, protein, and calorie supplementation are known to be helpful for sarcopenia, but the elderly, who make up the majority of sarcopenia patients, are not very helpful, so a treatment for sarcopenia is desperately needed. However, currently, the drugs used for sarcopenia have a direct effect on improving muscle loss and increasing muscle mass, and are still at the level of clinical trials, and there are currently no drugs that have been finally approved by the FDA. Therefore, there have been efforts to develop some selective androgen receptor modulators, activin receptor antagonists, and fast skeletal muscle troponin inhibitors as treatments for sarcopenia for the treatment of sarcopenia, but they are currently at the level of initial clinical trials.
따라서 근감소증 환자 또는 노인에게 섭취하기에 안전하고 장기 복용할 수 있는 천연물질을 이용한 운동능력 증가, 근력 증가 또는 근육량 증가와 같은 근기능 개선용 식품 조성물, 근기능 개선용 화장료 조성물, 근감소증의 개선 또는 예방용 식품 조성물 또는 근감소증의 치료 또는 예방용 약학 조성물이 요구되고 있다.Therefore, a food composition for improving muscle function, such as increasing exercise capacity, muscle strength, or muscle mass increase, using natural substances that are safe to consume for sarcopenia patients or the elderly and can be taken for a long time, cosmetic composition for improving muscle function, improvement or prevention of sarcopenia There is a demand for a food composition or a pharmaceutical composition for the treatment or prevention of sarcopenia.
한편 인삼의 유효성분 중 진세노사이드 Rg1 또는 Rb1이 근육 분화와 관련되어 있다는 보고가 있으나, 화기삼에서는 함유되지 않고 고려 인삼에서 특징적으로 존재하는 진세노사이드 Rf는 근육 분화, 근력 증강 또는 운동능력 향상 등과 관련이 있는지에 대해서 밝혀진 바 없다. On the other hand, it is reported that ginsenoside Rg1 or Rb1 among the active ingredients of ginseng is related to muscle differentiation, but ginsenoside Rf, which is not contained in Hwagisam and is characteristic of Korean ginseng, It has not been revealed whether it is relevant.
[선행기술문헌][Prior technical literature]
[특허문헌][Patent Literature]
대한민국 등록특허 제2011957호Korean Patent Registration No. 2011957
대한민국 등록특허 제1999916호Korean Registered Patent No. 1999916
[비특허문헌][Non-patent literature]
Ginsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube growth, 2017, Journal of Ginseng ResearchGinsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube growth, 2017, Journal of Ginseng Research
Ginsenoside Rb1 and Rb2 upregulate Akt/mTOR signalingemediated muscular hypertrophy and myoblast differentiation, 2019, Journal of Ginseng ResearchGinsenoside Rb1 and Rb2 upregulate Akt/mTOR signaling emediated muscular hypertrophy and myoblast differentiation, 2019, Journal of Ginseng Research
본 발명의 목적은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 식품 조성물을 제공하기 위한 것이다.An object of the present invention is to provide a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
또한, 본 발명의 다른 목적은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 화장료 조성물을 제공하기 위한 것이다.In addition, another object of the present invention is to provide a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
또한, 본 발명의 또 다른 목적은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증의 개선 또는 예방용 식품 조성물을 제공하기 위한 것이다.In addition, another object of the present invention is to provide a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving or preventing sarcopenia comprising a mixture of one or more of them as an active ingredient It is to do.
또한, 본 발명의 또 다른 목적은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증의 치료 또는 예방용 약학 조성물을 제공하기 위한 것이다.In addition, another object of the present invention is to provide a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a pharmaceutical composition for the treatment or prevention of sarcopenia comprising a mixture of one or more of them as an active ingredient It is to do.
상기한 목적을 달성하기 위한 본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 식품 조성물을 제공한다.The present invention for achieving the above object provides a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving muscle function comprising a mixture of one or more of them as an active ingredient.
또한 본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 화장료 조성물을 제공한다.In addition, the present invention provides a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
또한 본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증의 개선 또는 예방용 식품 조성물을 제공한다.In addition, the present invention provides a ginsenoside Rf, a ginsenoside composition comprising a ginsenoside Rf, or a food composition for improving or preventing sarcopenia comprising a mixture of one or more of them as an active ingredient.
또한 본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증의 치료 또는 예방용 약학 조성물을 제공한다.In addition, the present invention provides a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a pharmaceutical composition for the treatment or prevention of sarcopenia comprising a mixture of at least one of them as an active ingredient.
본 발명의 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물은 근육 분화 마커인 Myosin Heavy Chain 발현을 촉진시키고, 체내 에너지 항상성을 조절하고 골격근 발달 및 성장 조절에 중요한 역할을 수행하는 AMPK 인산화를 촉진시키며, 동물실험에서 강제유영시험에서 수영지속시간을 증가시켜 운동능력을 증가시키고, 근력을 증가시키고, 근육량을 증가시키며, 근위축을 완화시킬 수 있다. Ginsenoside Rf of the present invention, a ginsenoside composition comprising ginsenoside Rf, or a mixture of any one or more of them promotes the expression of Myosin Heavy Chain, a muscle differentiation marker, regulates energy homeostasis in the body, and develops and grows skeletal muscle It promotes phosphorylation of AMPK, which plays an important role in regulation, and can increase exercise capacity, increase muscle strength, increase muscle mass, and alleviate muscle atrophy by increasing swimming duration in the forced swimming test in animal experiments.
도 1은 진세노사이드 Rf, Rb2 및 Rg1을 각각 10, 20 및 40 μM로 처리했을 때의 MHC(Myosin Heavy Chain)의 발현을 웨스턴 블랏을 통해 확인한 사진이다.1 is a photograph confirming the expression of MHC (Myosin Heavy Chain) when ginsenosides Rf, Rb2 and Rg1 were treated with 10, 20 and 40 μM, respectively, through Western blot.
도 2는 도 1의 MHC(Myosin Heavy Chain)의 발현을 나타내는 웨스턴 블랏 밴드 크기를 액틴에 대한 상대 발현 정도를 비교한 그래프이다.FIG. 2 is a graph comparing the size of the western blot band representing the expression of MHC (Myosin Heavy Chain) of FIG. 1 with respect to actin.
도 3은 진세노사이드 Rf, Rb2 및 Rg1을 각각 10, 20 및 40 μM로 처리했을 때의 AMPK(5'-adenosine monophosphate-activated protein kinase)의 인산화를 웨스턴 블랏을 통해 확인한 사진이다.3 is a photograph confirming phosphorylation of 5′-adenosine monophosphate-activated protein kinase (AMPK) when ginsenosides Rf, Rb2 and Rg1 were treated with 10, 20 and 40 μM, respectively, through Western blot.
도 4는 도 3의 인산화된 p-AMPK(phosphorylated 5'-adenosine monophosphate-activated protein kinase)의 웨스턴 블랏 밴드 크기를 인산화되지 않은 AMPK(phosphorylated 5'-adenosine monophosphate-activated protein kinase)에 대한 상대 발현 정도를 비교한 그래프이다.Figure 4 is a relative expression level of the western blot band size of phosphorylated p-AMPK (phosphorylated 5'-adenosine monophosphate-activated protein kinase) of Figure 3 for non-phosphorylated AMPK (phosphorylated 5'-adenosine monophosphate-activated protein kinase) It is a graph comparing.
도 5는 진세노사이드 Rf 10 μM와 진세노사이드 Rh1 및 Rg2를 각각 0.2, 1 및 5 μM 병용 처리하였을 때의 MHC, PGC-1α, 인산화된 p-AMPK, 인산화된 p38을 웨스턴 블랏을 통해 확인한 사진이다.FIG. 5 shows MHC, PGC-1α, phosphorylated p-AMPK, phosphorylated p38 when 10 μM of ginsenoside Rf and 0.2, 1, and 5 μM of ginsenosides Rh1 and Rg2, respectively, were confirmed through Western blot. It's a picture.
도 6은 도 5의 MHC, PGC-1α, 인산화된 p-AMPK, 인산화된 p38의 액틴에 대한 상대 발현 정도를 비교한 그래프이다.6 is a graph comparing the relative expression levels of MHC, PGC-1α, phosphorylated p-AMPK, and phosphorylated p38 to actin of FIG. 5.
도 7은 진세노사이드 Rf 10 μM와 진세노사이드 Rk3 및 Rh4를 각각 0.2, 1 및 5 μM 병용 처리하였을 때의 MHC, PGC-1α, 인산화된 p-AMPK, 인산화된 p38을 웨스턴 블랏을 통해 확인한 사진이다.7 shows MHC, PGC-1α, phosphorylated p-AMPK, and phosphorylated p38 when ginsenoside Rf 10 μM and ginsenosides Rk3 and Rh4 were treated in combination with 0.2, 1 and 5 μM, respectively, confirmed through Western blot. It's a picture.
도 8은 도 7의 MHC, PGC-1α, 인산화된 p-AMPK, 인산화된 p38의 액틴에 대한 상대 발현 정도를 비교한 그래프이다.FIG. 8 is a graph comparing the relative expression levels of MHC, PGC-1α, phosphorylated p-AMPK, and phosphorylated p38 to actin of FIG. 7.
도 9는 화기삼(AG, 100 ㎍/mL)에 진세노사이드 Rf, Rb2 및 Rg1을 각각 10 및 20 μM 혼합하였을 때, MHC(Myosin Heavy Chain)의 발현을 웨스턴 블랏을 통해 확인하고, 액틴에 대한 상대 발현 정도를 나타낸 그래프이다.9 is when 10 and 20 μM of ginsenosides Rf, Rb2 and Rg1 were mixed in Hwagisam (AG, 100 μg/mL), respectively, to confirm the expression of MHC (Myosin Heavy Chain) through Western blot, and for actin It is a graph showing the relative expression level.
본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 식품 조성물에 관한 것이다.The present invention relates to a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
또한 본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 화장료 조성물에 관한 것이다.In addition, the present invention relates to a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
또한 본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증의 개선 또는 예방용 식품 조성물에 관한 것이다.The present invention also relates to a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving or preventing sarcopenia comprising a mixture of at least one of them as an active ingredient.
또한 본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증의 치료 또는 예방용 약학 조성물에 관한 것이다.In addition, the present invention relates to a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a pharmaceutical composition for the treatment or prevention of sarcopenia comprising a mixture of one or more of them as an active ingredient.
상기 조성물은 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 추가로 포함할 수 있다.The composition may further include a ginsenoside composition including ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of them.
상기 조성물은 진세노사이드 Rf 성분 100 중량부에 대하여 진세노사이드 Rh1 성분 1 내지 100 중량부, 2 중량부 이상, 5 중량부 이상, 10 중량부 이상, 20 중량부 이상, 30 중량부 이상, 40 중량부 이상일 수 있고, 90 중량부 이하, 80 중량부 이하, 70 중량부 이하, 60 중량부 이하일 수 있다.The composition comprises 1 to 100 parts by weight, 2 parts by weight or more, 5 parts by weight or more, 10 parts by weight or more, 20 parts by weight or more, 30 parts by weight or more, 40 parts by weight, based on 100 parts by weight of the ginsenoside Rf component. It may be at least 90 parts by weight, 80 parts by weight or less, 70 parts by weight or less, and 60 parts by weight or less.
상기 진세노사이드 Rf를 포함하는 진세노사이드 조성물은 파낙스속 식물 또는 그 추출물을 가열, 효소처리 및 발효 중에서 선택되는 어느 하나 이상의 공정으로 처리한 진세노사이드 Rf 농축물일 수 있다.The ginsenoside composition comprising the ginsenoside Rf may be a ginsenoside Rf concentrate obtained by treating a plant of the genus Panax or an extract thereof by any one or more processes selected from heating, enzyme treatment, and fermentation.
상기 진세노사이드 Rh1을 포함하는 진세노사이드 조성물은 파낙스속 식물 또는 그 추출물을 가열, 효소처리 및 발효 중에서 선택되는 어느 하나 이상의 공정으로 처리한 진세노사이드 Rf 농축물일 수 있다.The ginsenoside composition comprising the ginsenoside Rh1 may be a ginsenoside Rf concentrate obtained by treating a plant of the genus Panax or an extract thereof by any one or more processes selected from heating, enzyme treatment, and fermentation.
또한 상기 파낙스속 식물 추출물은 물, 탄소수 1 내지 4의 알코올 또는 그들의 혼합 용매에 의한 추출물일 수 있다. In addition, the plant extract of the genus Panax may be an extract using water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 물은 식품 제조에 적합할 경우 특별히 한정할 필요는 없으나 예를 들어 지하수, 정제수, 증류수, 탈이온수 등이 이용될 수 있다. When the water is suitable for food production, there is no need to specifically limit it, but for example, ground water, purified water, distilled water, deionized water, and the like may be used.
상기 탄소수 1 내지 4의 알코올은 특별히 한정할 필요는 없으나 예들 들어 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올 또는 노말-부탄올 등이 이용될 수 있고, 바람직하게는 에탄올이다. The alcohol having 1 to 4 carbon atoms is not particularly limited, but for example, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol or normal-butanol may be used, preferably ethanol.
상기 혼합 용매는 특별히 한정할 필요는 없으나 예를 들어 물과 에탄올의 혼합 용매인 경우 5 내지 95 중량% 에탄올 수용액, 10 내지 90 중량% 에탄올 수용액, 20 내지 80 중량% 에탄올 수용액, 30 내지 70 중량% 에탄올 수용액이 이용될 수 있다.The mixed solvent is not particularly limited, but for example, in the case of a mixed solvent of water and ethanol, 5 to 95% by weight aqueous ethanol solution, 10 to 90% by weight aqueous ethanol solution, 20 to 80% by weight aqueous ethanol solution, 30 to 70% by weight An aqueous ethanol solution can be used.
상기 물 추출물의 제조는 특별히 한정할 필요는 없으나 파낙스속 식물을 10 내지 100 ℃의 물로 2 내지 60시간 동안 추출하여 제조할 수 있다.The preparation of the water extract is not particularly limited, but can be prepared by extracting the plant of the genus Panax with water at 10 to 100° C. for 2 to 60 hours.
상기 알코올 추출물, 또는 물과 알코올의 혼합 용매의 추출물의 제조는 특별히 한정할 필요는 없으나 예를 들어 파낙스속 식물을 30 내지 70 중량%의 에탄올 수용액으로 20 내지 60 ℃에서 2 내지 48 시간 추출하여 제조한다.The preparation of the alcohol extract or the extract of a mixed solvent of water and alcohol is not particularly limited, but, for example, the plant of the genus Panax is prepared by extracting the genus Panax with an aqueous ethanol solution of 30 to 70% by weight at 20 to 60°C for 2 to 48 hours. do.
상기 파낙스속 식물은 고려인삼(Panax ginseng), 화기삼(Panax quinquefolia), 전칠삼(Panax notoginseng), 죽절삼(Panax japonica), 삼엽삼(Panax trifolia), 히말라야삼(Panax pseudoginseng), 베트남삼(Panax vietnamensis) 및 이들의 배양근 중에서 선택되는 어느 하나 이상일 수 있다.Plants of the genus Panax are Korean ginseng (Panax ginseng), Hwagi ginseng (Panax quinquefolia), Panax notoginseng, bamboo japonica, Panax trifolia, Himalayan ginseng (Panax pseudoginseng), Vietnamese ginseng (Panax vietnamensis). ) And may be any one or more selected from cultured roots thereof.
상기 파낙스속 식물은 상기 식물의 뿌리, 종자, 열매 및 잎 중에서 선택되는 어느 하나 이상일 수 있다.The plant of the genus Panax may be any one or more selected from roots, seeds, fruits, and leaves of the plant.
상기 진세노사이드 Rf를 포함하는 진세노사이드 조성물 또는 진세노사이드 Rh1을 포함하는 진세노사이드 조성물은 상기 파낙스속 식물의 추출물, 이들로부터 분획한 분획물, 이들 추출물 또는 분획물을 추가적으로 농축한 농축물, 이를 정제 또는 분리한 정제물도 포함하고, 상기 추출물, 분획물, 농축물 또는 정제물을 건조한 건조물 또는 그를 분쇄한 분말을 포함하는 의미로 사용된다. 상기 정제물의 제조를 위해 분자량 컷-오프 값을 갖는 한외 여과막을 통과시키거나, 또는 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 부가할 수 있다.The ginsenoside composition comprising the ginsenoside Rf or the ginsenoside composition comprising ginsenoside Rh1 is an extract of the genus Panax plant, a fraction fractionated from them, a concentrate obtained by additionally concentrating these extracts or fractions, Purified or separated purified product is also included, and the extract, fraction, concentrate, or purified product is dried or pulverized. For the preparation of the purified product, various additionally performed, such as passing through an ultrafiltration membrane having a molecular weight cut-off value, or separation by various chromatography (made for separation according to size, charge, hydrophobicity, or affinity) Purification methods can be added.
상기 조성물, 즉 1) 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 2) 진세노사이드 Rf 및 진세노사이드 Rf를 포함하는 진세노사이드 조성물의 혼합물, 또는 3) 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;과 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;의 혼합물은 진세노사이드 Rf, Rh1, Rg1 및 Rb2의 합으로 이루어지는 진세노사이드 전체 중량에서 진세노사이드 Rf를 30 중량% 이상, 35 중량% 이상, 40 중량% 이상, 45 중량% 이상, 50 중량% 이상, 60 중량% 이상, 또는 70 중량% 이상 포함할 수 있고, 또한 진세노사이드 Rf를 80 중량% 이하, 90 중량% 이하, 95 중량% 이하, 99 중량% 이하, 또는 100 중량% 이하 포함할 수 있으며, 진세노사이드 Rf 중량을 진세노사이드 Rg1 중량으로 나눈 값이 1 이상, 1.1 이상, 1.2 이상, 1.3 이상, 1.4 이상, 1.5 이상, 2 이상, 3 이상, 4 이상, 5 이상, 10 이상, 20 이상, 30 이상, 40 이상, 50 이상, 100 이상, 500 이상일 수 있고, 10000 이하, 5000 이하, 또는 1000 이하일 수 있다.The composition, that is, 1) a ginsenoside composition comprising ginsenoside Rf, or 2) a mixture of a ginsenoside composition comprising ginsenoside Rf and ginsenoside Rf, or 3) ginsenoside Rf, ginseno A ginsenoside composition comprising a side Rf, or a mixture of any one or more of them; and a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of these; a mixture of ginsenosides Ginsenoside Rf 30% by weight or more, 35% by weight or more, 40% by weight or more, 45% by weight or more, 50% by weight or more, 60% by weight of the total ginsenoside weight consisting of the sum of Rf, Rh1, Rg1 and Rb2 It may contain more than, or 70% by weight or more, and may contain 80% by weight or less, 90% by weight or less, 95% by weight or less, 99% by weight or less, or 100% by weight or less of ginsenoside Rf, and ginsenoside Rf Side Rf weight divided by ginsenoside Rg1 weight is 1 or more, 1.1 or more, 1.2 or more, 1.3 or more, 1.4 or more, 1.5 or more, 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, 20 or more, 30 It may be more than, 40 or more, 50 or more, 100 or more, 500 or more, and may be 10000 or less, 5000 or less, or 1000 or less.
상기 조성물, 즉 1) 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 2) 진세노사이드 Rf 및 진세노사이드 Rf를 포함하는 진세노사이드 조성물의 혼합물, 또는 3) 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;과 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;의 혼합물은 파낙사트리올 진세노사이드 전체 중량 중에서 진세노사이드 Rf를 20 중량% 이상, 22 중량% 이상, 25 중량% 이상, 30 중량% 이상, 35 중량% 이상, 40 중량% 이상, 45 중량% 이상, 50 중량% 이상, 60 중량% 이상, 또는 70 중량% 이상 포함할 수 있고, 또한 진세노사이드 Rf를 80 중량% 이하, 90 중량% 이하, 95 중량% 이하, 99 중량% 이하, 또는 100 중량% 이하 포함할 수 있으며, 상기 파낙사트리올 진세노사이드 전체 중량은 진세노사이드 Rg1, Rg2, Re, Rh1 및 Rf을 합한 중량일 수 있다.The composition, that is, 1) a ginsenoside composition comprising ginsenoside Rf, or 2) a mixture of a ginsenoside composition comprising ginsenoside Rf and ginsenoside Rf, or 3) ginsenoside Rf, ginseno A ginsenoside composition comprising a side Rf, or a mixture of any one or more of them; and a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of these; Ginsenoside Rf of 20% by weight or more, 22% by weight or more, 25% by weight or more, 30% by weight or more, 35% by weight or more, 40% by weight or more, 45% by weight or more, 50% by weight of the total weight of all ginsenosides It may contain more than, 60% by weight or more, or 70% by weight or more, and also include 80% by weight or less, 90% by weight or less, 95% by weight or less, 99% by weight or less, or 100% by weight or less of ginsenoside Rf. The total weight of the panaxatriol ginsenoside may be a total weight of ginsenosides Rg1, Rg2, Re, Rh1 and Rf.
상기 조성물, 즉 1) 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 2) 진세노사이드 Rf 및 진세노사이드 Rf를 포함하는 진세노사이드 조성물의 혼합물, 또는 3) 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;과 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;의 혼합물은 진세노사이드 전체 중량 중에서 진세노사이드 Rf를 10 중량% 이상, 12 중량% 이상, 15 중량% 이상, 20 중량% 이상, 25 중량% 이상, 30 중량% 이상, 35 중량% 이상, 40 중량% 이상, 45 중량% 이상, 50 중량% 이상, 60 중량% 이상, 또는 70 중량% 이상 포함할 수 있고, 또한 진세노사이드 Rf를 80 중량% 이하, 90 중량% 이하, 95 중량% 이하, 99 중량% 이하, 또는 100 중량% 이하 포함할 수 있으며, 상기 진세노사이드 전체 중량은 진세노사이드 Rg1, Rg2, Re, Rh1 및 Rf을 합한 파낙사트리올 진세노사이드 전체 중량 및 진세노사이드 Rb1, Rb2, Rg3, Rh2, Rc 및 Rd를 합한 파낙사디올 진세노사이드 전체 중량을 합한 중량일 수 있다.The composition, that is, 1) a ginsenoside composition comprising ginsenoside Rf, or 2) a mixture of a ginsenoside composition comprising ginsenoside Rf and ginsenoside Rf, or 3) ginsenoside Rf, ginseno A ginsenoside composition comprising a side Rf, or a mixture of any one or more of them; and a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of these; a mixture of ginsenosides Ginsenoside Rf in the total weight of 10% by weight or more, 12% by weight or more, 15% by weight or more, 20% by weight or more, 25% by weight or more, 30% by weight or more, 35% by weight or more, 40% by weight or more, 45% by weight % Or more, 50% by weight or more, 60% by weight or more, or 70% by weight or more, and also 80% by weight or less, 90% by weight or less, 95% by weight or less, 99% by weight or less, or It may contain less than 100% by weight, and the total weight of the ginsenosides is the total weight of the ginsenosides Rg1, Rg2, Re, Rh1 and Rf combined panaxatriol ginsenosides and ginsenosides Rb1, Rb2, Rg3, Rh2 , Rc and Rd may be the sum of the total weight of panaxadiol ginsenoside.
상기 '유효성분으로 포함하는'이란 1) 진세노사이드 Rf, 2) 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 3) 이들 중 어느 하나 이상의 혼합물, 또는 4) 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;과 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;의 혼합물의 효능을 달성하는 데 충분한 양을 포함하는 것을 의미한다. The term'contained as an active ingredient' means 1) ginsenoside Rf, 2) ginsenoside composition comprising ginsenoside Rf, or 3) any one or more mixtures of these, or 4) ginsenoside Rf, ginseno A ginsenoside composition comprising a side Rf, or a mixture of any one or more of them; and a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of these; Achieving the efficacy of a mixture of It means to contain enough amount to do.
상기 근기능 개선에서 '근(筋)'은 심줄, 근육, 건을 포괄적으로 지칭하고, '근기능'은 근육의 수축에 의해 힘을 발휘할 수 있는 능력을 의미하며, 근육이 저항을 이겨내기 위하여 최대한의 수축력을 발휘할 수 있는 근력; 근육이 주어진 중량에 얼마나 오랫동안 또는 얼마나 여러 번 수축과 이완을 반복할 수 있는지 나타내는 능력인 근 지구력; 및 단시간 내에 강한 힘을 발휘하는 능력인 순발력을 포함한다. 예를 들어 근기능 개선은 운동능력 증가, 근력 증가 및 근육량 증가 중에서 선택되는 어느 하나일 수 있다.In the above muscle function improvement,'muscle' refers to tendons, muscles, and tendons generically, and'muscle function' refers to the ability to exert power by contraction of muscles. Muscle strength capable of exerting contractility; Muscle endurance, the ability to describe how long or how many times a muscle can contract and relax for a given weight; And instantaneous power, which is an ability to exert a strong power within a short time. For example, the improvement of muscle function may be any one selected from an increase in exercise capacity, an increase in muscle strength, and an increase in muscle mass.
상기 근감소증은 근기능 저하, 근육 소모 또는 근육 퇴화로 인한 근육의 부피 및 근력이 점진적으로 쇠퇴하는 질환을 의미하고, 근위축증, 근무력증, 근이영양증, 근경직증, 근긴장저하, 근력약화, 근육퇴행위축, 근위축성 측삭경화증 및 중증 근무력증 중에서 선택되는 어느 하나일 수 있다.The sarcopenia refers to a disease in which muscle volume and muscle strength gradually decline due to muscle function decline, muscle wasting or muscle degeneration, and muscle atrophy, myasthenia, muscle dystrophy, muscle stiffness, muscle tone reduction, muscle weakness, muscle regression, muscle atrophy. It may be any one selected from lateral sclerosis and myasthenia gravis.
본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 또는 근감소증 개선 또는 예방용 식품 조성물에 관한 것이다.The present invention relates to a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a food composition for improving muscle function or improving or preventing sarcopenia, comprising a mixture of one or more of them as an active ingredient.
상기 식품 조성물은 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 추가로 포함할 수 있다.The food composition may further include a ginsenoside composition including ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of them.
상기 '식품 조성물'은 유효성분으로 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물 이외에, 식품 제조에 통상적으로 사용되는 식품의 기준 및 규격('식품공전')에 기재된 식품으로 사용가능한 식품 원료, 식품첨가물 공전에 기재된 식품첨가물을 포함한다.In addition to the ginsenoside composition including ginsenoside Rf and ginsenoside Rf as active ingredients, or any one or more mixtures of these, the'food composition' is a standard and standard of food commonly used in food production ('food Food ingredients and food additives that can be used as foods described in the code') include food additives described in the code.
특별히 한정할 필요는 없으나 예를 들어 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상기 탄수화물은 단당류, 예를 들어, 포도당, 과당 등; 이당류, 예를 들어 말토스, 설탕, 유당 등; 올리고당 또는 폴리사카라이드, 예를 들어 덱스트린, 물엿, 사이클로덱스트린 등; 당알코올, 예를 들어 자일리톨, 소르비톨, 에리트리톨 등을 사용할 수 있다. 상기 향미제는 천연 향미제[타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.It does not need to be particularly limited, but includes, for example, proteins, carbohydrates, fats, nutrients, flavoring agents and flavoring agents. The carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sugar, lactose, and the like; Oligosaccharides or polysaccharides such as dextrin, starch syrup, cyclodextrin, and the like; Sugar alcohols such as xylitol, sorbitol, erythritol, and the like can be used. The flavoring agent may be a natural flavoring agent [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and a synthetic flavoring agent (saccharin, aspartame, etc.).
상기 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 식품 조성물을 제조하는 경우 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물은 근기능 개선 또는 근감소증의 개선 효능을 나타내는 함량이면 특별히 한정할 필요는 없으나, 예를 들어 0.1 내지 99 중량%, 0.5 내지 95 중량%, 1 내지 90 중량%, 2 내지 80 중량%, 3 내지 70 중량%, 4 내지 60 중량%, 5 내지 50 중량%로 포함될 수 있다.Ginsenoside comprising ginsenoside Rf, ginsenoside Rf when preparing a food composition using the ginsenoside Rf, ginsenoside Rf, or a mixture of any one or more of them as an active ingredient The composition, or a mixture of any one or more thereof, does not need to be particularly limited as long as it is an amount exhibiting an effect of improving muscle function or sarcopenia, but, for example, 0.1 to 99% by weight, 0.5 to 95% by weight, 1 to 90% by weight, It may be included in 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, and 5 to 50% by weight.
상기 식품 조성물에서 유효성분인 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물은 섭취자의 상태, 체중, 질병의 유무나 정도 및 기간에 따라 다르지만, 통상의 기술자에 의해 적절하게 선택될 수 있다. 예들 들어 1일 투여량을 기준으로 1 내지 5,000 mg, 바람직하게는 5 내지 2,000 mg, 더욱 바람직하게는 10 내지 1,000 mg, 더더욱 바람직하게는 20 내지 800 mg, 가장 바람직하게는 50 내지 500 mg일 수 있고, 투여 횟수는 특별히 한정할 필요는 없으나 1일 3회 내지 1주일에 1회의 범위 내에서 통상의 기술자가 조절할 수 있다. 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있다.The ginsenoside composition comprising ginsenoside Rf and ginsenoside Rf, which are active ingredients in the food composition, or a mixture of any one or more of them varies depending on the condition of the ingestor, weight, the presence or absence of disease, and the duration, but usually It can be appropriately selected by the technician of For example, it may be 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, even more preferably 20 to 800 mg, most preferably 50 to 500 mg, based on the daily dosage. In addition, the number of administrations does not need to be particularly limited, but can be adjusted by a person skilled in the art within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, it may be less than the above range.
상기 식품 조성물은 특별히 한정할 필요는 없으나 예를 들어 산제, 과립제, 정제, 캡슐제, 환제, 엑스제, 젤리 제형, 티백 제형 또는 음료 제형일 수 있다.The food composition is not particularly limited, but may be, for example, a powder, a granule, a tablet, a capsule, a pill, an extract, a jelly formulation, a tea bag formulation, or a beverage formulation.
또한 일반 식품에 자외선에 의한 근기능 개선 또는 근감소증 개선 기능성을 부여하기 위하여 상기 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 첨가할 수 있으며, 첨가가 가능한 식품은, 특별히 한정할 필요는 없으나 예를 들어 식품위생법 제7조에 따른 식품의 기준 및 규격('식품공전')에 예시된 과자류, 빵 또는 떡류, 코코아가공품류 또는 초콜릿류, 식육 또는 알가공품, 어육가공품, 두부류 또는 묵류, 면류, 다류, 커피, 음료류, 특수용도식품, 장류, 조미식품, 드레싱류, 김치류, 젓갈류, 절임식품, 조림식품, 주류, 건포류, 기타 식품류 등에 첨가될 수 있다. 또한 축산물위생관리법 제4조에 따른 축산물의 가공기준 및 성분규격('축산물공전')에 예시된 유가공품, 식육가공품 및 포장육, 알가공품에 첨가될 수 있다.In addition, a ginsenoside composition including the ginsenoside Rf and ginsenoside Rf, or a mixture of any one or more of these may be added in order to impart the function of improving muscle function or sarcopenia to general foods due to ultraviolet rays. Foods that can be allowed are not particularly limited, but for example, confectionery, bread or rice cakes, processed cocoa products or chocolates, meat or eggs exemplified in the food standards and standards ('Food Code') according to Article 7 of the Food Sanitation Act. Processed products, processed fish products, tofu or jelly, noodles, tea, coffee, beverages, special purpose foods, pastes, seasoned foods, dressings, kimchi, salted fish, pickles, stewed foods, alcoholic beverages, raisins, and other foods. I can. In addition, it may be added to dairy products, processed meat products and packaged meats, and egg products as exemplified in the processing standards and ingredient specifications of livestock products pursuant to Article 4 of the Livestock Hygiene Management Act ('Livestock Products Code').
한편 상기 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 하는 식품 조성물은 단독으로 "근기능 개선에 도움을 주는 건강기능식품"으로 이용될 수 있고, "근력 증강에 도움을 주는 건강기능식품", "운동능력 증강에 도움을 주는 건강기능식품" 또는 "근감소증 개선에 도움을 주는 건강기능식품"으로 이용될 수 있다. Meanwhile, the ginsenoside composition comprising the ginsenoside Rf, ginsenoside Rf, or a food composition comprising any one or more of these as an active ingredient may be used as a "health functional food that helps improve muscle function" It can be used as "health functional food that helps to enhance muscle strength", "health functional food that helps to increase exercise capacity", or "health functional food that helps to improve sarcopenia".
상기 '건강기능식품'은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 법적 기준에 따라 제조(가공을 포함)한 식품(건강기능식품에 관한 법률 제3조 제1호)을 말한다. 상기 '건강기능식품'은 국가마다 용어나 범위에 차이가 있을 수 있으나, 미국의 '식이 보충제(Dietary Supplement)', 유럽의 '식품 보충제(Food Supplemnet)', 일본의 '보건기능식품' 또는 '특정보건용식품(Food for Special Health Use, FoSHU)', 중국의 '보건식품' 등에 해당할 수 있다.The'health functional food' refers to a food (including processing) manufactured (including processing) according to legal standards using raw materials or ingredients having useful functions for the human body (Article 3, No. 1 of the Health Functional Food Act). The'health functional food' may differ in terms or ranges from country to country, but'Dietary Supplement' in the United States,'Food Supplemnet' in Europe, and'Health Functional Food' in Japan or ' It may correspond to'Food for Special Health Use (FoSHU)' and'Health Food' in China.
상기 식품 조성물 또는 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, 식품첨가물로서의 적합여부는 다른 규정이 없는 한 '식품첨가물공전'의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 따른다.The food composition or health functional food may additionally contain food additives, and the suitability as a food additive is determined according to the standards and standards for the relevant item in accordance with the general rules and general test methods of the'Food Additive Code' unless otherwise specified. Follows.
또한 상기 건강기능식품에는 상기 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물과 함께 근기능 개선 또는 근감소증 개선과 관련된 건강기능식품 소재를 복합하여 사용할 수 있다.In addition, the health functional food may be used in combination with a ginsenoside composition including the ginsenoside Rf and ginsenoside Rf, or a health functional food material related to improvement of muscle function or sarcopenia with a mixture of one or more of them. have.
본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 화장료 조성물에 관한 것이다.The present invention relates to a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of at least one of them as an active ingredient.
상기 화장료 조성물은 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 추가로 포함할 수 있다.The cosmetic composition may further include a ginsenoside composition including ginsenoside Rh1, ginsenoside Rh1, or a mixture of one or more of them.
상기 근기능 개선용 화장료 조성물로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 유화제, 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 활성제, 친유성 활성제 또는 지질 소낭 등 피부 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.When used as the cosmetic composition for improving muscle function, additionally fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water , Ionic emulsifiers, nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic activators, lipophilic activators or lipid vesicles, etc. It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients used as. In addition, the above ingredients may be introduced in an amount generally used in the field of dermatology.
상기 화장료 조성물 특별히 제한하는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제 등의 제형일 수 있다.The cosmetic composition is not particularly limited, but may be a formulation such as an ointment, patch, gel, cream or spray.
본 발명은 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증 치료 또는 예방용 약학 조성물에 관한 것이다.The present invention relates to a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a pharmaceutical composition for treating or preventing sarcopenia comprising a mixture of at least one of them as an active ingredient.
상기 약학 조성물은 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 추가로 포함할 수 있다.The pharmaceutical composition may further include a ginsenoside composition including ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of them.
또한 본 발명은 인간, 또는 인간을 제외한 동물에게 상기 조성물을 투여하는 근감소증의 치료방법을 제공한다.In addition, the present invention provides a method for treating sarcopenia by administering the composition to humans or animals other than humans.
또한 본 발명은 근감소증 치료용 의약 제조를 위한 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물의 신규 용도를 제공한다.In addition, the present invention provides a novel use of a ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or a mixture of any one or more of them for the manufacture of a medicine for the treatment of sarcopenia.
상기 '약학 조성물' 또는 '의약'은 유효성분으로 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물 이외에, 약학 조성물 등의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The'pharmaceutical composition' or'medicine' is a ginsenoside composition including ginsenoside Rf and ginsenoside Rf as an active ingredient, or a mixture of any one or more of them, as well as suitable for conventional use in the manufacture of pharmaceutical compositions, etc. It may further include a carrier, excipient and diluent.
상기 '담체'는 세포 또는 조직 내로의 화합물의 부가를 용이하게 하는 화합물이다. 상기 '희석제'는 대상 화합물의 생물학적 활성 형태를 안정화시킬 뿐만 아니라, 화합물을 용해시키게 되는 물에서 희석되는 화합물이다. The'carrier' is a compound that facilitates the addition of the compound into cells or tissues. The'diluent' is a compound that is diluted in water to dissolve the compound as well as stabilize the biologically active form of the target compound.
상기 담체, 부형제 및 희석제로는 특별히 한정할 필요는 없으나 예를 들어, 유당, 포도당, 설탕, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 들 수 있다.The carrier, excipient and diluent do not need to be particularly limited, but for example, lactose, glucose, sugar, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
상기 약학 조성물 또는 의약의 사용량은 환자 또는 치료대상 동물의 나이, 성별, 체중에 따라 달라질 수 있으며, 무엇보다도, 치료대상 개체의 상태, 치료 대상 질환의 특정한 카테고리 또는 종류, 투여 경로, 사용되는 치료제의 속성에 의존적일 것이다.The amount of use of the pharmaceutical composition or drug may vary depending on the age, sex, and weight of the patient or the animal to be treated, and above all, the condition of the subject to be treated, the specific category or type of the disease to be treated, the route of administration, and the therapeutic agent used. It will be attribute dependent.
상기 약학 조성물 또는 의약은 체내에서 활성성분의 흡수도, 배설속도, 환자 또는 치료대상 동물의 연령 및 체중, 성별 및 상태, 치료할 질병의 중증정도 등에 따라 적절히 선택되나, The pharmaceutical composition or medicament is appropriately selected according to the degree of absorption of the active ingredient in the body, the excretion rate, the age and weight, sex and condition of the patient or the animal to be treated, the severity of the disease to be treated, etc.
일반적으로 1일 0.1 내지 1,000mg/kg, 바람직하게는 1 내지 500mg/kg, 더욱 바람직하게는 5 내지 250mg/kg, 가장 바람직하게는 10 내지 100mg/kg으로 투여하는 것이 바람직하다. 이렇게 제형화 된 단위 투여형 제제는 필요에 따라 일정시간 간격으로 수회 투여할 수 있다.In general, it is preferred to administer 0.1 to 1,000 mg/kg per day, preferably 1 to 500 mg/kg, more preferably 5 to 250 mg/kg, and most preferably 10 to 100 mg/kg per day. The unit dosage form formulation thus formulated can be administered several times at regular time intervals as needed.
상기 약학 조성물 또는 의약은 개별적으로 예방제 또는 치료제로서 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다.The pharmaceutical composition or medicament may be individually administered as a prophylactic or therapeutic agent, or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent.
상기 약학조성물 또는 의약은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 트로키제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구 제형으로 제형화하여 사용될 수 있다. 제형화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.Each of the pharmaceutical compositions or drugs may be formulated and used in oral dosage forms such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc., according to conventional methods. In the case of formulation, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제, 트로키제 등이 포함되며, 이러한 고형 제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트, 설탕 또는 유당, 젤라틴 등을 섞어 조제될 수 있다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, and the like, and these solid preparations include at least one excipient for the compound, such as starch, calcium carbonate, sugar or lactose, gelatin. It can be prepared by mixing and the like. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. .
상기 근감소증의 치료방법은 인간, 또는 인간을 제외한 동물, 특히 포유동물에게 상기 1) 진세노사이드 Rf, 2) 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 3) 이들 중 어느 하나 이상의 혼합물, 또는 4) 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;과 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물;의 혼합물을 경구 투여 하는 것으로, 예를 들어 근감소증을 가진 치료대상 개체에게 상기 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 경구 투여하는 것이다.The method for treating sarcopenia is a ginsenoside composition comprising 1) ginsenoside Rf, 2) ginsenoside Rf, or 3) a mixture of any one or more of these in humans or non-human animals, particularly mammals. , Or 4) ginsenoside composition comprising ginsenoside Rf, ginsenoside Rf, or any one or more mixtures thereof; and ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or among these By oral administration of a mixture of any one or more mixtures, for example, a ginsenoside composition comprising the ginsenoside Rf, ginsenoside Rf, or a mixture of any one or more thereof to an individual to be treated with sarcopenia It is administered orally.
상기 근감소증을 가진 치료대상 개체 여부는, 전술한 피부 수분 손실량 증대, 피부 수분 함유량 감소, 피부 거칠기 증대, 피부 탄력 감소된 경우 일 수 있다. Whether or not the subject to be treated with sarcopenia may be the case where the amount of skin moisture loss is increased, the skin moisture content is decreased, the roughness of the skin is increased, and the elasticity of the skin is decreased.
상기 치료를 위한 투여량, 투여 방법 및 투여 횟수는 상기 약학 조성물 또는 의약의 투여량, 투여 방법 및 투여 횟수를 참고할 수 있다.The dosage, administration method, and number of administrations for the treatment may refer to the dosage, administration method, and number of administrations of the pharmaceutical composition or drug.
이하, 바람직한 실시예를 들어 본 발명을 더욱 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이에 의하여 제한되지 않는다는 것은 당업계의 통상의 지식을 가진 자에게 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to preferred examples. However, these examples are intended to illustrate the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited thereto.
실험예 1: 진세노사이드 Rf의 근육분화 효과 확인Experimental Example 1: Checking the muscle differentiation effect of ginsenoside Rf
고려인삼의 특이 성분 진세노사이드 Rf의 농도별 처리시 근육 분화 바이오 마커인 MHC (myosin heavy chain)의 발현을 웨스턴 블랏 방법을 이용해 확인하였다. Expression of MHC (myosin heavy chain), a muscle differentiation biomarker, was confirmed by Western blot method when the concentration of ginsenoside Rf, a specific component of Korean ginseng, was treated by concentration.
C2C12 근육세포는 American Type Culture Collection (ATCC)에서 구입하여 사용하였다. C2C12 근육세포는 37℃, 5% CO2조건의 배양기에서 10% FBS, 1%항생제를 포함한 DMEM배지를 이용하여 배양하였다. 2% horse serum DMEM배지로 교체하면 근육의 분화가 유도되고, 근육 세포(C2C12)에 분화유도 조건 (DM, 2% horse serum DMEM배지) 처리 2일 후에 진세노사이드 Rf, Rg1 및 Rb2를 각각 처리하였다 C2C12 muscle cells were purchased and used from the American Type Culture Collection (ATCC). C2C12 muscle cells were cultured in a DMEM medium containing 10% FBS and 1% antibiotic in an incubator at 37°C and 5% CO2. When replacing with 2% horse serum DMEM medium, muscle differentiation is induced, and ginsenosides Rf, Rg1 and Rb2 are treated 2 days after treatment with differentiation inducing conditions (DM, 2% horse serum DMEM medium) in muscle cells (C2C12). Did
단백질 발현 변화를 확인하기 위해 웨스턴 블랏 방법을 이용하였다. 위에 언급한 방법으로 준비된 세포 펠렛을 protease inhibitor와 phosphatase inhibitor가 첨가된 cell lysis buffer (cell signaling)를 이용하여 시료를 준비하였다. BCA방법으로 단백질을 정량 한 후, 동량의 단백질을 SDS sample buffer와 섞고, 95℃에서 10분간 가열하여 단백질을 변성시켜 실험에 이용한다. 시료를 gradient SDS-polyacrylamide 젤에 전기영동하였다. 젤의 단백질을 니트로셀룰로오스(NC) 멤브레인에 트랜스퍼 한 후, 5% 스킴 밀크용액으로 실온에서 1시간 블로킹한다. 그 후 1차 항체를 4℃조건에서 하룻밤 배양한 후 HRP가 붙어있는 적절한 2차 항체를 붙여 ECL용액을 이용하여 chemiluminescent 방법으로 각각의 단백질 발현을 확인하여 도 1에 나타내었다.Western blot method was used to confirm the change in protein expression. The cell pellet prepared by the above method was prepared using a cell lysis buffer (cell signaling) to which a protease inhibitor and a phosphatase inhibitor were added. After quantifying the protein by the BCA method, the same amount of the protein is mixed with the SDS sample buffer and heated at 95° C. for 10 minutes to denature the protein to be used in the experiment. Samples were electrophoresed on gradient SDS-polyacrylamide gel. After transferring the protein of the gel to a nitrocellulose (NC) membrane, blocking is performed for 1 hour at room temperature with a 5% skim milk solution. Thereafter, the primary antibody was incubated overnight at 4° C., and then the appropriate secondary antibody with HRP was added, and the expression of each protein was confirmed by chemiluminescent method using an ECL solution, as shown in FIG. 1.
진세노사이드 Rg1의 근육분화 효능은 "Ginsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube growth, 2017, Journal of Ginseng Research"에 기재되어 있고, 진세노사이드 Rb2의 근육분화 효능은 "Ginsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube growth, 2017, Journal of Ginseng Research"에 기재되어 있으므로, 이들 진세노사이드들을 양성 대조군으로 이용하였다.The muscle differentiation efficacy of ginsenoside Rg1 is described in "Ginsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube growth, 2017, Journal of Ginseng Research". As described in myoblast differentiation and myotube growth, 2017, Journal of Ginseng Research", these ginsenosides were used as positive controls.
종래 근육분화 효능이 공지된 진세노사이드 Rg1 및 Rh2에 비해서 진세노사이드 Rf에서 MHC단백질 발현을 증가시킴을 확인하였다(도 1 및 2 참조). 특히 20 μM 농도에서 진세노사이드 Rf가 진세노사이드 Rg1에 비해서 근육분화 효능이 4.1 배 증가하였고, 40 μM 농도에서 진세노사이드 Rf가 진세노사이드 Rb2에 비해서 근육분화 효능이 5.3배 증가하였다.It was confirmed that the MHC protein expression was increased in ginsenoside Rf compared to ginsenosides Rg1 and Rh2, which are known for their muscle differentiation efficacy (see FIGS. 1 and 2). In particular, at a concentration of 20 μM, ginsenoside Rf increased muscle differentiation efficacy by 4.1 times compared to ginsenoside Rg1, and at 40 μM concentration, ginsenoside Rf increased muscle differentiation efficacy by 5.3 times compared to ginsenoside Rb2.
실험예 2: 진세노사이드 Rf의 에너지 대사 증가 효과 확인Experimental Example 2: Confirmation of the effect of increasing energy metabolism of ginsenoside Rf
근육분화는 에너지 대사의 증가로 인해 일어나기도 한다. AMPK (5'-adenosine monophosphate-activated protein kinase)는 체내 에너지 항상성을 조절하는 주요 효소로는 골격근 발달 및 성장 조절에 중요한 역할을 한다고 알려져 있다. 진세노사이드 Rf, Rb2 및 Rg1처리에 의한 에너지대사와 관련된 시그널 단백질인 AMPK인산화의 변화를 실험예 1의 웨스턴 블랏 방법을 이용하여 확인하고, 그 결과를 도 3 및 도 4에 나타내었다. Muscle differentiation can also occur due to an increase in energy metabolism. AMPK (5'-adenosine monophosphate-activated protein kinase) is a major enzyme that regulates energy homeostasis in the body and is known to play an important role in skeletal muscle development and growth regulation. Changes in AMPK phosphorylation, a signal protein related to energy metabolism by treatment with ginsenosides Rf, Rb2 and Rg1, were confirmed using the Western blot method of Experimental Example 1, and the results are shown in FIGS. 3 and 4.
진세노사이드 Rf, Rb2 및 Rg1처리에 의해 에너지대사와 관련이 있다고 잘 알려진 마커인 AMPK의 인산화가 모두 증가하였다.Ginsenosides Rf, Rb2 and Rg1 treatment all increased phosphorylation of AMPK, a well-known marker related to energy metabolism.
특히 20 μM 및 40 μM 농도 모두에서 진세노사이드 Rf는 진세노사이드 Rb2 및 Rg1에 비해서 AMPK의 인산화를 현저히 증가시켰다. 따라서 진세노사이드 Rf는 AMPK 인산화를 통해 근육 분화를 유도하는데 영향을 주었음을 알 수 있다. In particular, at both concentrations of 20 μM and 40 μM, ginsenoside Rf significantly increased phosphorylation of AMPK compared to ginsenosides Rb2 and Rg1. Therefore, it can be seen that ginsenoside Rf had an effect on inducing muscle differentiation through AMPK phosphorylation.
실험예 3: 진세노사이드 Rf 다른 진세노사이드들과의 상승효과 확인Experimental Example 3: Ginsenoside Rf Synergistic effect with other ginsenosides confirmed
진세노사이드 Rf는 고려인삼(Panax ginseng) 및 이로부터 제조한 홍삼에 특이적으로 존재하는 진세노사이드로서, 진세노사이드 Rf가 다른 진세노사이드들과 함께 작용하여 근육분화 및 에너지 대사 증가에 상승효과를 나타내는지 확인하였다.Ginsenoside Rf is a ginsenoside that is specifically present in Korean ginseng (Panax ginseng) and red ginseng produced therefrom. Ginsenoside Rf works with other ginsenosides to increase muscle differentiation and energy metabolism. It was confirmed whether it showed an effect.
진세노사이드 Rf와 복합 투여되는 진세노사이드들로는 백삼에 비해 홍삼 추출물에서 그 함량이 증가한다고 알려진 진세노사이드 Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 및 Rg5 총 7종의 진세노사이드들을 대상으로 하였다.Ginsenosides Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 and Rg5 are 7 types of ginsenosides, which are known to increase their content in red ginseng extract compared to white ginseng. Sides were targeted.
실험예 1과 동일하게 준비된 C2C12 근육세포를 분화유도 조건 (DM, 2% horse serum DMEM배지) 처리 2일 후에 진세노사이드 Rf를 각각 5, 10 및 20μM 처리하고, Rf 10μM과 함께 진세노사이드 Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 및 Rg5 총 7종의 진세노사이드를 각각 0.2, 1 및 5 μM 병용 처리하였다.C2C12 muscle cells prepared in the same manner as in Experimental Example 1 were treated with differentiation inducing conditions (DM, 2% horse serum DMEM medium) 2 days after treatment with ginsenoside Rf 5, 10 and 20 μM, respectively, and ginsenoside Rh1 with Rf 10 μM , Rg2, Rk3, Rh4, Rk1, (S)-Rg3 and Rg5 A total of 7 ginsenosides were treated in combination with 0.2, 1 and 5 μM, respectively.
실험예 1과 동일하게 단백질 발현 변화를 확인하기 위해 웨스턴 블랏 방법을 이용하였고(도 5 및 도 7 참조), 상대적인 단백질 발현 정도는 Image J program을 사용하여 계산하여 도 6 및 도 8에 나타내었다(진세노사이드 Rk1, (S)-Rg3 및 Rg5 결과는 나타내지 않음).In the same manner as in Experimental Example 1, a Western blot method was used to confirm the protein expression change (see FIGS. 5 and 7), and the relative protein expression level was calculated using the Image J program and shown in FIGS. 6 and 8 ( Ginsenosides Rk1, (S)-Rg3 and Rg5 results are not shown).
진세노사이드 Rf와 복합 투여되는 진세노사이드 Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 및 Rg5 총 7종의 진세노사이드 중에서 Rh1과 병용 처리한 경우에서만 Rf 단독 처리한 경우에 비해 근육 분화 바이오 마커인 MHC (myosin heavy chain)의 발현을 증가시켰고, 특히 Rf 100 중량부에 대하여 Rh1 10 내지 50 중량부로 처리한 경우 상승효과를 나타내었다(도 5 및 도 6 참조).Ginsenosides Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 and Rg5 administered in combination with ginsenoside Rf, compared to the case of Rf alone treatment only in combination with Rh1 among a total of 7 ginsenosides. The expression of the muscle differentiation biomarker MHC (myosin heavy chain) was increased, and in particular, when treated with 10 to 50 parts by weight of Rh1 with respect to 100 parts by weight of Rf, it exhibited a synergistic effect (see FIGS. 5 and 6).
에너지 대사와 관련된 인산화된 p-AMPK, PGC-1α 및 인산화된 p-p38을 웨스턴 블랏 후 상대적인 단백질 발현 정도를 확인한 결과, 상위 조절인자인 인산화된 p-AMPK에서는 상승효과가 명확히 확인되지 않았으나, PGC-1α 및 인산화된 p-p38에 있어서 진세노사이드 Rf와 복합 투여되는 진세노사이드 Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 및 Rg5 총 7종의 진세노사이드 중에서 Rh1과 병용 처리한 경우에서만 Rf 단독 처리한 경우에 비해 유의적인 상승효과를 나타내었고, 특히 가장 중요한 지표인 인산화된 p-p38에 있어서 Rf 100 중량부에 대하여 Rh1 2 내지 50 중량부로 처리한 경우 유의적인 상승효과를 나타내었고, 특히 Rh1이 2 내지 10 중량부인 경우 더욱 높은 상승효과를 나타내었다(도 5 및 도 6 참조).As a result of confirming the relative protein expression level of phosphorylated p-AMPK, PGC-1α and phosphorylated p-p38 related to energy metabolism after Western blot, the synergistic effect was not clearly confirmed in the phosphorylated p-AMPK, the upper regulator, but PGC Ginsenosides Rh1, Rg2, Rk3, Rh4, Rk1, (S)-Rg3 and Rg5 administered in combination with ginsenosides Rf for -1α and phosphorylated p-p38 are treated in combination with Rh1 among a total of 7 ginsenosides Only one case showed a significant synergistic effect compared to the case of Rf alone treatment, and in particular, for the phosphorylated p-p38, which is the most important index, a significant synergistic effect was achieved when treatment with Rh1 2 to 50 parts by weight per 100 parts by weight of Rf In particular, when Rh1 was 2 to 10 parts by weight, a higher synergistic effect was exhibited (see FIGS. 5 and 6).
실험예 4: 진세노사이드 Rf를 포함하는 진세노사이드 조성물의 근육분화 효능 확인Experimental Example 4: Checking the muscle differentiation efficacy of a ginsenoside composition containing ginsenoside Rf
화기삼은 Wisconsin산 건삼을 이용하였다. 화기삼 1g에 50배의 증류수로 80℃에서 환류냉각추출기를 이용하여 2시간씩 3번 반복하여 열수 추출하였다. 상등액을 Whatman No2 필터지를 이용해 여과한 후 감압농축하고, 증류수에 다시 희석한 후 동결건조하여 화기삼 열수 추출물을 제조하였다.Dry ginseng from Wisconsin was used for Hwagisam. Hot water extraction was performed 3 times for 2 hours each using a reflux cooling extractor at 80°C with 50 times the amount of distilled water to 1 g of Hwagisam. The supernatant was filtered using Whatman No2 filter paper, concentrated under reduced pressure, diluted again in distilled water, and freeze-dried to prepare a hot water extract of Hwagisam.
상기 화기삼 열수 추출물은 진세노사이드 Rf는 포함하고 있지 않았고, 진세노사이드 Rg1은 0.32 mg/g, 진세노사이드 Rb2는 0.33 mg/g 포함하고 있었다.The Hwagisam hot water extract did not contain ginsenoside Rf, ginsenoside Rg1, 0.32 mg/g, and ginsenoside Rb2, 0.33 mg/g.
상기 화기삼 열수 추출물(100 ㎍/mL)에 진세노사이드 Rf를 각각 10 μM 및 20μM을 혼합하여 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 상기 화기삼 열수 추출물(100 ㎍/mL)에 진세노사이드 Rg1을 각각 10 μM 및 20μM을 혼합하여 진세노사이드 Rg1를 포함하는 진세노사이드 조성물, 상기 화기삼 열수 추출물(100 ㎍/mL)에 진세노사이드 Rb2를 각각 10 μM 및 20μM을 혼합하여 진세노사이드 Rb2를 포함하는 진세노사이드 조성물을 각각 제조하였다.Ginsenoside composition containing ginsenoside Rf by mixing 10 μM and 20 μM of ginsenoside Rf in the Hwagisam hot water extract (100 μg/mL), ginsenoside in the Hwagi ginseng hot water extract (100 μg/mL) Ginsenoside composition containing ginsenoside Rg1 by mixing 10 μM and 20 μM of Rg1, ginsenoside Rb2 in the Hwagisam hot water extract (100 μM/mL), respectively, by mixing 10 μM and 20 μM of ginsenoside Rb2 Each ginsenoside composition comprising a was prepared.
근육 분화 바이오 마커인 MHC (myosin heavy chain)의 발현을 실험예 1과 동일한 웨스턴 블랏 방법을 이용해 확인하여 그 결과를 도 9에 나타내었다.Expression of the muscle differentiation biomarker MHC (myosin heavy chain) was confirmed using the same western blot method as in Experimental Example 1, and the results are shown in FIG. 9.
진세노사이드 Rg1을 각각 10 μM 및 20μM을 혼합한 진세노사이드 Rg1를 포함하는 진세노사이드 조성물, 진세노사이드 Rb2를 각각 10 μM 및 20μM을 혼합하여 진세노사이드 Rb2를 포함하는 진세노사이드 조성물에서는 MHC 발현 증가를 확인할 수 없었으나, 화기삼 열수 추출물(100 ㎍/mL)에 진세노사이드 Rf를 각각 10 μM 및 20μM을 혼합하여 진세노사이드 Rf를 포함하는 진세노사이드 조성물에서는 MHC의 발현이 각각 1.77배 및 1.6배 증가함을 확인하였다.In the ginsenoside composition comprising ginsenoside Rg1, which is a mixture of 10 μM and 20 μM of ginsenoside Rg1, respectively, 10 μM and 20 μM of ginsenoside Rb2, respectively, and the ginsenoside composition containing ginsenoside Rb2 Although the increase in MHC expression could not be confirmed, the expression of MHC was 1.77 in the ginsenoside composition containing ginsenoside Rf by mixing 10 μM and 20 μM of ginsenoside Rf in Hwagisam hot water extract (100 μg/mL), respectively. It was confirmed that the increase was doubled and 1.6-fold.
하기에 본 발명의 진세노사이드 Rf, 또는 진세노사이드 Rf를 포함하는 진세노사이드 조성물을 포함하는 식품, 화장료 또는 약학 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, examples of the preparation of a food, cosmetic or pharmaceutical composition comprising a ginsenoside Rf or ginsenoside composition comprising a ginsenoside Rf of the present invention will be described, but the present invention is not intended to limit it, but only specifically I am trying to explain.
제제예 1. 산제의 제조Formulation Example 1. Preparation of powder
진세노사이드 Rf 500 mgGinsenoside Rf 500 mg
유당 100 mg100 mg lactose
탈크 10 mg10 mg of talc
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
진세노사이드 Rf 300 mgGinsenoside Rf 300 mg
옥수수전분 100 mg100 mg corn starch
유당 100 mg100 mg lactose
스테아린산 마그네슘 2 mg2 mg of magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet manufacturing method.
제제예 3. 캅셀제의 제조Formulation Example 3. Preparation of Capsule
진세노사이드 Rf 200 mgGinsenoside Rf 200 mg
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mg14.8 mg lactose
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
진세노사이드 Rf 600 mgGinsenoside Rf 600 mg
만니톨 180 mgMannitol 180 mg
주사용 멸균 증류수 2974 mg2974 mg of sterile distilled water for injection
Na2HPO4,12H2O 26 mgNa 2 HPO 4, 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플 당 상기의 성분 함량으로 제조한다.It is prepared with the above ingredients per ampoule according to a conventional injection preparation method.
제제예 5. 액제의 제조Formulation Example 5. Preparation of liquid formulation
진세노사이드 Rf 4 gGinsenoside Rf 4 g
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water appropriate amount
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100g으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to the usual preparation method of liquid formulations, add and dissolve each component in purified water, add an appropriate amount of lemon scent, mix the above ingredients, add purified water and add purified water to adjust the total to 100 g, then fill in a brown bottle for sterilization. To prepare a liquid formulation.
제제예 6. 과립제의 제조Formulation Example 6. Preparation of granules
진세노사이드 Rf 1중량% 함유 진세노사이드 조성물 1,000 mg1,000 mg of ginsenoside composition containing 1% by weight of ginsenoside Rf
비타민 혼합물 적량The right amount of vitamin mixture
비타민 A 아세테이트 70 ㎍Vitamin A acetate 70 ㎍
비타민 E 1.0 mg1.0 mg of vitamin E
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mg0.5 mg of vitamin B6
비타민 B12 0.2 ㎍Vitamin B12 0.2 ㎍
비타민 C 10 mg10 mg of vitamin C
비오틴 10 ㎍Biotin 10 ㎍
니코틴산아미드 1.7 mg1.7 mg of nicotinic acid amide
엽산 50 ㎍Folic acid 50 ㎍
판토텐산 칼슘 0.5 mg0.5 mg of calcium pantothenate
무기질 혼합물 적량Suitable amount of inorganic mixture
황산제1철 1.75 mgFerrous sulfate 1.75 mg
산화아연 0.82 mgZinc oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgDicalcium phosphate 55 mg
구연산칼륨 90 mg90 mg of potassium citrate
탄산칼슘 100 mg100 mg of calcium carbonate
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 과립제에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 과립제 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixture is relatively suitable for granules, but it is also possible to arbitrarily modify the mixing ratio. After mixing the above ingredients according to a conventional granule preparation method, granules And can be used to prepare a health functional food composition according to a conventional method.
제제예 7. 기능성 음료의 제조Formulation Example 7. Preparation of functional beverage
진세노사이드 Rf 1중량% 함유 진세노사이드 조성물 1,000 mg1,000 mg of ginsenoside composition containing 1% by weight of ginsenoside Rf
구연산 1,000 mg1,000 mg citric acid
올리고당 100 g100 g oligosaccharides
매실농축액 2 g2 g of plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 mL900 mL total by adding purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. After mixing the above ingredients according to the normal health drink manufacturing method, stirring and heating the mixture at 85°C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator. It is used to prepare the functional beverage composition of the present invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.The composition ratio is a mixture of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.

Claims (20)

  1. 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 식품 조성물.Ginsenoside Rf, a ginsenoside composition comprising a ginsenoside Rf, or a food composition for improving muscle function comprising a mixture of one or more of them as an active ingredient.
  2. 제1항에 있어서, 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 추가로 포함하는 것을 특징으로 하는 근기능 개선용 식품 조성물.The food composition for improving muscle function according to claim 1, further comprising a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of them.
  3. 제2항에 있어서, 상기 조성물은 진세노사이드 Rf 성분 100 중량부에 대하여 진세노사이드 Rh1 성분 1 내지 100 중량부 함유하는 것을 특징으로 하는 근기능 개선용 식품 조성물.The food composition for improving muscle function according to claim 2, wherein the composition contains 1 to 100 parts by weight of the ginsenoside Rh1 component based on 100 parts by weight of the ginsenoside Rf component.
  4. 제1항에 있어서, 상기 진세노사이드 Rf를 포함하는 진세노사이드 조성물은 파낙스속 식물 또는 그 추출물을 가열, 효소처리 및 발효 중에서 선택되는 어느 하나 이상의 공정으로 처리한 진세노사이드 Rf 농축물인 것을 특징으로 하는 근기능 개선용 식품 조성물.The method of claim 1, wherein the ginsenoside composition comprising the ginsenoside Rf is a ginsenoside Rf concentrate obtained by treating a plant of the genus Panax or an extract thereof by any one or more processes selected from heating, enzyme treatment, and fermentation. Food composition for improving muscle function.
  5. 제2항에 있어서, 상기 진세노사이드 Rh1을 포함하는 진세노사이드 조성물은 파낙스속 식물 또는 그 추출물을 가열, 효소처리 및 발효 중에서 선택되는 어느 하나 이상의 공정으로 처리한 진세노사이드 Rf 농축물인 것을 특징으로 하는 근기능 개선용 식품 조성물.The method of claim 2, wherein the ginsenoside composition comprising the ginsenoside Rh1 is a ginsenoside Rf concentrate obtained by treating a plant of the genus Panax or an extract thereof by one or more processes selected from heating, enzyme treatment, and fermentation. Food composition for improving muscle function.
  6. 제4항 또는 제5항에 있어서, 상기 파낙스속 식물은 고려인삼(Panax ginseng), 화기삼(Panax quinquefolia), 전칠삼(Panax notoginseng), 죽절삼(Panax japonica), 삼엽삼(Panax trifolia), 히말라야삼(Panax pseudoginseng), 베트남삼(Panax vietnamensis) 및 이들의 배양근 중에서 선택되는 어느 하나 이상인 것을 특징으로 하는 근기능 개선용 식품 조성물.6. (Panax pseudoginseng), Vietnamese ginseng (Panax vietnamensis) and a food composition for improving muscle function, characterized in that at least one selected from cultured roots thereof.
  7. 제6항에 있어서, 상기 파낙스속 식물은 상기 식물의 뿌리, 종자, 열매 및 잎 중에서 선택되는 어느 하나 이상인 것을 특징으로 하는 근기능 개선용 식품 조성물.The food composition for improving muscle function according to claim 6, wherein the plant of the genus Panax is any one or more selected from roots, seeds, fruits, and leaves of the plant.
  8. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 조성물은 진세노사이드 Rf, Rh1, Rg1 및 Rb2의 합으로 이루어지는 진세노사이드 전체 중량에서 진세노사이드 Rf를 30 중량% 이상 포함하고, 진세노사이드 Rf 중량을 진세노사이드 Rg1 중량으로 나눈 값이 1 이상인 것을 특징으로 하는 근기능 개선용 식품 조성물. The method of any one of claims 1 to 5, wherein the composition comprises at least 30% by weight of ginsenoside Rf in the total weight of ginsenosides consisting of the sum of ginsenosides Rf, Rh1, Rg1 and Rb2, and Food composition for improving muscle function, characterized in that the value obtained by dividing the weight of senoside Rf by the weight of ginsenoside Rg1 is 1 or more.
  9. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 조성물은 파낙사트리올 진세노사이드 전체 중량 중에서 진세노사이드 Rf를 20 중량% 이상 포함하고, 상기 파낙사트리올 진세노사이드 전체 중량은 진세노사이드 Rg1, Rg2, Re, Rh1 및 Rf을 합한 중량인 것을 특징으로 하는 근기능 개선용 식품 조성물. The method of any one of claims 1 to 5, wherein the composition contains at least 20% by weight of ginsenoside Rf among the total weight of panaxatriol ginsenoside, and the total weight of panaxatriol ginsenoside is Ginsenosides Rg1, Rg2, Re, Rh1 and Rf food composition for improving muscle function, characterized in that the combined weight.
  10. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 조성물은 진세노사이드 전체 중량 중에서 진세노사이드 Rf를 10 중량% 이상 포함하고, 상기 진세노사이드 전체 중량은 진세노사이드 Rg1, Rg2, Re, Rh1 및 Rf을 합한 파낙사트리올 진세노사이드 전체 중량 및 진세노사이드 Rb1, Rb2, Rg3, Rh2, Rc 및 Rd를 합한 파낙사디올 진세노사이드 전체 중량을 합한 중량인 것을 특징으로 하는 근기능 개선용 식품 조성물. The method of any one of claims 1 to 5, wherein the composition comprises at least 10% by weight of ginsenoside Rf among the total weight of ginsenoside, and the total weight of ginsenoside is ginsenoside Rg1, Rg2, Re , Rh1 and Rf combined total weight of panaxatriol ginsenoside and ginsenoside Rb1, Rb2, Rg3, Rh2, Rc and Rd combined total weight of panaxadiol ginsenoside Food composition.
  11. 제1항에 있어서, 상기 근기능 개선은 운동능력 증가, 근력 증가 및 근육량 증가 중에서 선택되는 어느 하나인 것을 특징으로 하는 근기능 개선용 식품 조성물.The food composition for improving muscle function according to claim 1, wherein the muscle function improvement is any one selected from an increase in exercise capacity, an increase in muscle strength, and an increase in muscle mass.
  12. 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근기능 개선용 화장료 조성물.Ginsenoside Rf, a ginsenoside composition comprising a ginsenoside Rf, or a cosmetic composition for improving muscle function comprising a mixture of one or more of them as an active ingredient.
  13. 제12항에 있어서, 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 추가로 포함하는 것을 특징으로 하는 근기능 개선용 화장료 조성물.The cosmetic composition for improving muscle function according to claim 12, further comprising a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of any one or more of them.
  14. 제11항 또는 제12항에 있어서, 상기 근기능 개선은 운동능력 증가, 근력 증가 및 근육량 증가 중에서 선택되는 어느 하나인 것을 특징으로 하는 근기능 개선용 화장료 조성물.The cosmetic composition for improving muscle function according to claim 11 or 12, wherein the muscle function improvement is any one selected from an increase in exercise capacity, an increase in muscle strength, and an increase in muscle mass.
  15. 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증의 개선 또는 예방용 식품 조성물.Ginsenoside Rf, ginsenoside composition comprising a ginsenoside Rf, or a food composition for improving or preventing sarcopenia comprising a mixture of one or more of them as an active ingredient.
  16. 제15항에 있어서, 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 추가로 포함하는 것을 특징으로 하는 근감소증의 개선 또는 예방용 식품 조성물.The food composition for improving or preventing sarcopenia according to claim 15, further comprising a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of one or more of them.
  17. 제15항 또는 제16항에 있어서, 상기 근감소증은 근위축증, 근무력증, 근이영양증, 근경직증, 근긴장저하, 근력약화, 근육퇴행위축, 근위축성 측삭경화증 및 중증 근무력증 중에서 선택되는 어느 하나인 것을 특징으로 하는 근감소증의 개선 또는 예방용 식품 조성물.The method of claim 15 or 16, wherein the sarcopenia is any one selected from muscular atrophy, myasthenia, muscular dystrophy, muscular stiffness, hypotonia, muscle weakness, muscular dystrophy, amyotrophic lateral sclerosis, and severe myasthenia gravis. Food composition for improving or preventing sarcopenia.
  18. 진세노사이드 Rf, 진세노사이드 Rf를 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 유효성분으로 포함하는 근감소증의 치료 또는 예방용 약학 조성물.Ginsenoside Rf, a ginsenoside composition comprising a ginsenoside Rf, or a pharmaceutical composition for the treatment or prevention of sarcopenia comprising a mixture of one or more of them as an active ingredient.
  19. 제18항에 있어서, 진세노사이드 Rh1, 진세노사이드 Rh1을 포함하는 진세노사이드 조성물, 또는 이들 중 어느 하나 이상의 혼합물을 추가로 포함하는 것을 특징으로 하는 근감소증의 치료 또는 예방용 약학 조성물.The pharmaceutical composition for the treatment or prevention of sarcopenia according to claim 18, further comprising a ginsenoside composition comprising ginsenoside Rh1, ginsenoside Rh1, or a mixture of one or more of them.
  20. 제18항 또는 제19에 있어서, 상기 근감소증은 근위축증, 근무력증, 근이영양증, 근경직증, 근긴장저하, 근력약화, 근육퇴행위축, 근위축성 측삭경화증 및 중증 근무력증 중에서 선택되는 어느 하나인 것을 특징으로 하는 근감소증의 치료 또는 예방용 약학 조성물.The muscle of claim 18 or 19, wherein the sarcopenia is any one selected from muscular atrophy, myasthenia gravis, muscular dystrophy, muscular stiffness, hypotonia, muscle weakness, muscular dystrophy, amyotrophic lateral sclerosis, and severe myasthenia gravis. Pharmaceutical composition for the treatment or prevention of hypothyroidism.
PCT/KR2020/014832 2019-10-28 2020-10-28 Composition for muscular function enhancement comprising ginsenoside rf, ginsenoside composition comprising ginsenoside rf, or mixture of any one or more thereof as active ingredient WO2021086017A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20190134639 2019-10-28
KR10-2019-0134639 2019-10-28
KR1020200140963A KR102483300B1 (en) 2019-10-28 2020-10-28 Composition for improving muscle atrophy comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component
KR10-2020-0140963 2020-10-28

Publications (1)

Publication Number Publication Date
WO2021086017A1 true WO2021086017A1 (en) 2021-05-06

Family

ID=75715409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/014832 WO2021086017A1 (en) 2019-10-28 2020-10-28 Composition for muscular function enhancement comprising ginsenoside rf, ginsenoside composition comprising ginsenoside rf, or mixture of any one or more thereof as active ingredient

Country Status (2)

Country Link
KR (1) KR102649974B1 (en)
WO (1) WO2021086017A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002053467A (en) * 2000-05-31 2002-02-19 Japan Science & Technology Corp SKIN TISSUE REGENERATION PROMOTER COMPRISING GINSENOSIDE Rb1
JP2002249498A (en) * 2001-02-21 2002-09-06 Japan Science & Technology Corp Antiapoptosis preparation or regeneration accelerating reagent containing ginesenosides derivatives
KR101771486B1 (en) * 2015-06-25 2017-08-25 서울대학교산학협력단 The method for preparing panax ginseng extract with increased contents of selective dammaranes, and a pharmaceutical compositions of the same for prevention or treatment of sarcopenia-related diseases
KR101917794B1 (en) * 2018-05-10 2018-11-13 한국과학기술원 Pharmaceutical composition for improving, preventing or treating muscle related disease comprising ginsenoside Rh2
KR101966117B1 (en) * 2018-05-25 2019-04-05 (주)녹십자웰빙 Composition comprising extract of processed ginseng for stimulating of myogenesis
KR20190084722A (en) * 2018-01-09 2019-07-17 숙명여자대학교산학협력단 Compositions for muscle regeneration comprising Ginsenoside Rg1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101750779B1 (en) * 2015-03-20 2017-06-27 샘표식품 주식회사 Composition for anti-fatigue containing aglycone ppd and/or ppt
KR102011957B1 (en) 2016-06-08 2019-08-19 재단법인 아산사회복지재단 Composition for treating or preventing sarcopenia using SLIT-ROBO system
JP6626035B2 (en) 2017-04-10 2019-12-25 グリーン クロス ウェルビーイング コーポレーションＧｒｅｅｎ Ｃｒｏｓｓ Ｗｅｌｌｂｅｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ Pharmaceutical composition for prevention or treatment of sarcopenia and health food composition for prevention or improvement
KR101999916B1 (en) 2018-01-19 2019-07-12 강릉원주대학교산학협력단 Composition for enhancement of muscular strength and preventing or treating of sarcopenia comprising Colpomenia bullosa extract
KR102053208B1 (en) * 2018-03-15 2019-12-06 숙명여자대학교 산학협력단 Compositions for muscle regeneration containing Ginsenoside Rb1 and Rb2 as active ingedients

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002053467A (en) * 2000-05-31 2002-02-19 Japan Science & Technology Corp SKIN TISSUE REGENERATION PROMOTER COMPRISING GINSENOSIDE Rb1
JP2002249498A (en) * 2001-02-21 2002-09-06 Japan Science & Technology Corp Antiapoptosis preparation or regeneration accelerating reagent containing ginesenosides derivatives
KR101771486B1 (en) * 2015-06-25 2017-08-25 서울대학교산학협력단 The method for preparing panax ginseng extract with increased contents of selective dammaranes, and a pharmaceutical compositions of the same for prevention or treatment of sarcopenia-related diseases
KR20190084722A (en) * 2018-01-09 2019-07-17 숙명여자대학교산학협력단 Compositions for muscle regeneration comprising Ginsenoside Rg1
KR101917794B1 (en) * 2018-05-10 2018-11-13 한국과학기술원 Pharmaceutical composition for improving, preventing or treating muscle related disease comprising ginsenoside Rh2
KR101966117B1 (en) * 2018-05-25 2019-04-05 (주)녹십자웰빙 Composition comprising extract of processed ginseng for stimulating of myogenesis

Also Published As

Publication number Publication date
KR20220120526A (en) 2022-08-30
KR102649974B1 (en) 2024-03-22

Similar Documents

Publication Publication Date Title
WO2011052846A1 (en) Pharmaceutical composition containing extracts of native plants as active ingredients for preventing or treating cancer
WO2015002391A1 (en) Composition having a function for alleviating premenstrual syndrome and menstrual pain
WO2018174448A1 (en) Composition for treating and preventing climacteric syndrome containing combined herbal medicinal extract of white atractylis, mori fructus, chinese matrimony vine, longan, achyranthes, eucommia bark, and asparagus cochinchinensis merr. as active ingredient, and use of same
WO2014058142A1 (en) Pharmaceutical composition containing aster glehni extract as active ingredientfor preventing or treating obesity or metabolic diseases
WO2010107170A1 (en) Composition for treating metabolic diseases
KR102483300B1 (en) Composition for improving muscle atrophy comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component
WO2016190566A9 (en) Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient
WO2021080297A1 (en) Composition containing evening primrose flower extract as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby
WO2014035035A1 (en) Pharmaceutical composition containing complex extract of aurantii nobilis pericarpium and crataegus as an active ingredient for treating or preventing obesity or lipid-related metabolic diseases
WO2013151192A1 (en) Composition comprising eupatorium spp. extract as active ingredient for preventing and treating obesity and metabolic bone disease
WO2015174636A1 (en) Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof
WO2016010340A1 (en) Composition for preventing and treating inflammation or allergic diseases, containing gynura procumbens extract as active ingredient, and use thereof
WO2023106777A1 (en) Vital melon (kctc14699bp) and anti-obesity composition comprising extract thereof
WO2021086017A1 (en) Composition for muscular function enhancement comprising ginsenoside rf, ginsenoside composition comprising ginsenoside rf, or mixture of any one or more thereof as active ingredient
WO2019209061A1 (en) Bone growth-promoting composition comprising allium fistulosum linn as active ingredient
WO2013069934A1 (en) Composition for treating and preventing obesity, containing wheatgrass extract as active ingredient
WO2017082478A1 (en) Pharmaceutical composition for preventing or treating osteoporosis comprising soybean germinated embryo extract
WO2023003204A1 (en) Anti-obesity composition containing rosa davurica extract as active ingredient
WO2010008150A2 (en) Composition for the prevention or treatment of osteoporosis, containing a mixture of saururus chinensis and scutellaria baicalensis extracts as an active ingredient
WO2015167240A1 (en) Composition containing scutellaria alpina extract
WO2021080298A1 (en) Composition containing enteroccocus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby
WO2021040416A1 (en) Pharmaceutical composition, for preventing or treating bone loss induced by metabolic bone diseases, comprising artemisia scoparia extract as active ingredient
WO2012105816A2 (en) Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof
WO2019078381A1 (en) Pharmaceutical composition, food composition and food additive for preventing, alleviating or treating muscle loss, weakness and atrophy, containing, as active ingredient, enterococcus faecalis, culture liquid thereof or dead cells thereof
WO2021033994A1 (en) Composition comprising salvia miltiorrhiza or paeonia lactiflora extract as active ingredient for prevention or treatment of lipid metabolism disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20881553

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20881553

Country of ref document: EP

Kind code of ref document: A1